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Cardiovascular diseases (CVDs), relating to heart and circulatory system, are among the 
leading causes of death worldwide. In developing countries, 31% of mortality rate is due to 
CVDs, and it has been estimated that it will become the major cause of deaths by 2020 
(Stewart et al., 2017). A wide spectrum of cardiac and vascular pathologies such as cardiac 
fibrosis, reduced angiogenesis after myocardial infarction (MI), atherosclerosis and cardiac 
hypertrophy are some important forms of CVDs (World Health organization report 2014-
2017) (Banquet et al., 2011; Carmeliet, 2005).  
• Cardiac fibrosis is referred as abnormal thickening of cardiac muscles with 
deposition of extracellular matrix (ECM), which reduces the mechanical function of 
heart (Tian et al., 2017). In normal cardiac function, cardiac fibroblasts maintain the 
ECM secretion like Collagen I and III in cardiac tissues (Nicoletti and Michel, 1999). 
This homeostatic balance of ECM is necessary to maintain mechanical force and 
electrical conductance in heart tissue (Travers et al., 2016). Hypertension, 
hyperglycemia and ischemia effect these fibroblasts leading to transforming them into 
myofibroblasts which secrete altered ECM proteins, mainly high amount of Collagen I 
(Nicoletti and Michel, 1999). This altered ECM reduces the cardiac tissue efficiency 
and promotes fibrosis, which leads to cardiac failure (Nicoletti and Michel, 1999; 
Travers et al., 2016). 
• Myocardial infarction (MI), also known as heart attack, occurs when there is 
insufficient blood supply to cardiac tissues (ischemia) (Kobayashi et al., 2017). 
Angiogenesis, formation of new capillaries is a response of cardiac tissue to 
compensate the ischemic condition (Hueso et al., 2017; Kobayashi et al., 2017). 
Reduced angiogenesis is a common pathological condition in CVDs (Kobayashi et al., 
2017). Prolonged ischemic conditions can lead to metabolic imbalance in ischemic 
tissues, which leads to cardiac failure (Hueso et al., 2017). Therapeutic studies focused 
on improving cardiac angiogenesis after MI shows that it results in reduced risk of 
cardiac failure (Hueso et al., 2017; Kobayashi et al., 2017).  
• Atherosclerosis is another common pathological condition associated with 
prognosis of multiple CVDs. Atherosclerosis is a disease, in which plaques develop 
inside the arterial walls (Verstraete, 1990; Zampetaki et al., 2010). Disturbed blood 
flow, hypertension and high cholesterol levels in blood exerts stress on arterial wall, 
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which leads to endothelial cells (ECs) dysfunction (Kwak et al., 2014; Zampetaki et al., 
2010). ECs dysfunction leads to atherosclerotic plaque development (Kwak et al., 
2014). Unstable plaques in atherosclerosis can rupture and activate the immune 
system, which develops a thrombus (Kwak et al., 2014).      
• Cardiac hypertrophy is defined as abnormal enlargement of cardiac muscles due 
to increased size of cardiomyocytes and deposition of ECM as a result of prolonged 
cardiac fibrosis (Hara et al., 2017). Cardiac chambers, specifically left ventricle, 
become enlarge due to deposition of excess ECM, which leads to cardiomyocyte death 
(Samak et al., 2016). Hypertrophic tissues become stiff and reduce the blood pumping 
efficiency of heart, which can lead to cardiac failure (Heineke and Molkentin, 2006; 
Samak et al., 2016). 
Among several forms of CVDs, atherosclerosis and cardiac hypertrophy are the focus of 
this thesis and will be discussed further in detail. Multiple environmental and biological 
factors contribute in the development of CVDs. Major risk factors for the development of 
atherosclerosis and cardiac hypertrophy can be divided into two categories: 1. Modifiable 
risk factors (diabetes, hypertension, elevated levels of cholesterol, obesity, and smoking) 
and 2. Non-modifiable risk factors (Aging, ethnicity, family history/genetic and gender).  
 
1.1 Modifiable risk factors in CVDs 
Modifiable risk factors include those factors, which are preventable and can reduce the risk 
of developing atherosclerosis or cardiac hypertrophy. Major modifiable risk factors are 
diabetes, hypertension, elevated levels of cholesterol in blood, obesity and smoking (Fig. 








Figure 1.1. Risk Factors in CVDs. Modifiable risk factors (green) are those that can be controlled or improved. These 
include diabetes, hypertension, cholesterol, obesity and smoking. Non-modifiable factors (red) are those that cannot be 
altered like age, ethnicity and family history (Genetic contribution) of disease. 
 
1.1.1 Diabetes 
Diabetes, also known as hyperglycemia (high blood sugar level) is classified as a 
modifiable risk factor. Once developed, it cannot be cured completely. However controlling 
blood sugar levels can reduce the risk of CVDs development (Leon and Maddox, 2015). 
Hyperglycemia leads to glycation of cholesterol molecule, which enhances its oxidation 
thereby leads to ECs dysfunction and promotes CVDs (Rosiek and Leksowski, 2016). The 
endothelium (ECs) is not only important to maintain homeostatic balance between blood 
and tissues (Fig. 1.2A) (Hadi et al., 2005; Messner and Bernhard, 2014), but also for non-
adhesive, anticoagulant, anti-hypertrophic and anti-inflammatory functions of endothelium 
dependent vasodilation (Hadi et al., 2005; Michaelis, 2014). Intriguingly, Insulin resistance 
and hyperglycemia contributes to the development of atherosclerosis and ECs dysfunction 
via reducing the production of endothelial Nitric Oxide Synthase (eNOS) and by enhanced 
production of Reactive Oxygen Species (ROS) (Leon and Maddox, 2015). The low levels 
of eNOS production leads to reduced ECs-dependent-vasodilation. While elevated levels 
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of ROS cause cell death and injury in ECs, which leads to inflammatory response and the 
development of CVDs (Leon and Maddox, 2015). 
1.1.2 Hypertension 
Hypertension, or high blood pressure, is developed  by environmental and genetic factors 
and contributes significantly to mortality associated with CVDs. It is known that persons 
with hypertension have 50% more chances to develop heart diseases compared to non-
hypertensive person (Huq et al., 2018). Hypertension increases the risk of ECs dysfunction 
and atherosclerosis probably by increasing ROS production and various vasoconstrictors 
such as endothelin-1 (ET-I) and Angiotension II (Ang-II), production (Higashi et al., 2012; 
Rosiek and Leksowski, 2016). Elevated levels of ROS and vasoconstrictors disrupt ECs 
dependent vasodilation and leads to the development of CVDs (Bleakley et al., 2015; 
Higashi et al., 2012).  
1.1.3 Elevated levels of Cholesterol 
Cholesterol is classified as one of the major contributing factor in CVDs development 
(Rosiek and Leksowski, 2016). High levels of low-density lipoprotein cholesterol (LDL-
Cholesterol) and triglycerides, collectively known as dyslipidemia, impairs ECs function by 
perturbing the eNOS signalling pathway (Dart and Chin-Dusting, 1999; Kim et al., 2012). 
Nitric Oxide (NO), a vasodilatory gas, derived from eNOS signalling pathway, is 
responsible for maintaining anti-apoptotic and anti-proliferative environment in blood 
vessels (Sessa, 2004).  Dyslipidemia is also known to stimulate leukocyte adhesion to ECs, 
therefore, contributes in atherosclerosis development (Dart and Chin-Dusting, 1999). LDL-
Cholesterol also contributes in progression of atherosclerotic lesions formation and is a 
dominating contributing molecule in lipid core of atherosclerotic lesions (Hadi et al., 2005; 
Rosiek and Leksowski, 2016).  
1.1.4 Obesity 
Obesity is a multifactorial disorder, in which both genetic and environmental factors are 
involved (Wang and Nakayama, 2010). Obesity indirectly increases the risk for CVDs 
development as a result of the development of diabetes, hypertension, and high levels of 
cholesterol in blood (Kachur et al., 2017). It has been reported that obese children have 
impaired contractile function and develop left ventricular hypertrophy (Jing et al., 2016). 
Obesity leads to disruption in lipid metabolism and increases ECs dysfunction due to 
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increased inflammation (Lovren et al., 2015). These attributes of obesity make a person 
more prone to develop atherosclerosis as compared to non-obese persons (Lovren et al., 
2015). 
1.1.5 Smoking 
Smoking is directly linked to multiple diseases like lung cancer, ischemia, atherosclerosis, 
endothelial dysfunction, hypoxemia, and thrombosis (Hadi et al., 2005). Smoking impairs 
the balance between endothelium specific vasoconstrictor and vasodilatory chemical 
production (Messner and Bernhard, 2014; Michael Pittilo, 2000). Smoking has been also 
reported as a contributing factor in lipid profile alteration and to increase the expression of 
adhesion molecules on ECs and reduce eNO production, which leads to endothelial 
dysfunction and atherosclerosis development (Messner and Bernhard, 2014).  
1.2 Non-modifiable Risk factors in CVDs 
Non-modifiable risk factors are those, which cannot be controlled or modified. These 
include Aging, ethnic background and family history. 
1.2.1 Aging 
Age is an independent risk factor that increases the risk of CVDs development in together 
with other risk factors such as diabetes, hypertension and high cholesterol levels (Dhingra 
and Vasan, 2011). Advanced age is associated with cellular senescence of ECs, loss of 
blood vessels elasticity (Hadi et al., 2005; Stewart et al., 2017) higher ROS production, 
which results in endothelial dysfunction and loss of ECs vasodilation ability (Higashi et al., 
2012; Matz and Andriantsitohaina, 2003).  
1.2.2 Ethnic background 
It has been reported that South Asian population has higher risk of CVDs development as 
compared to European population. This is mainly due to life style differences, which lead 
to the development of diabetes, high LDL-Cholesterol levels and hypertension (Chaturvedi, 
2003). Mexicans and African Americans are also reported to have higher risk of CVDs 
development (Chaturvedi, 2003; Forouhi and Sattar, 2006).  
1.2.3 Family History/Genetic factor 
Linkage analysis and genetic association studies have been one of a successful approach 
in determining CVDs development (Kathiresan and Srivastava, 2012). Risk of developing 
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CVDs increases if first-degree and second-degree relatives are affected (Imes and Lewis, 
2014). Risk of atherosclerosis development increases up to 3-fold if parents are 
atherosclerotic (Kathiresan and Srivastava, 2012). There is a 40% higher chance of CVDs 
development if a sibling is affected, while children of CVDs patients have 75% higher 
chance of developing CVDs (Imes and Lewis, 2014; Kolber and Scrimshaw, 12014). 
Taken together, all the above-mentioned factors independently and synergistically 
contribute in the development of CVDs, including atherosclerosis and cardiac hypertrophy 
(Hadi et al., 2005; Rosiek and Leksowski, 2016).  
 
1.3 Atherosclerosis 
Atherosclerosis refers to the thickening of arterial wall, which occurs due to the 
accumulation of lipids and fibrous materials in major arteries. Mostly the branched areas, 
which are exposed to disturbed blood flow are more prone to plaque development (Chien, 
2008; Zampetaki et al., 2010). There are three main layers in artery (Fig. 1.2A). The tunica 
intima is the inner most layer that is lined by monolayer of ECs. The middle layer, tunica 
media, mainly consists of smooth muscle cells (SMCs) that are embedded in ECM. The 
outer most layer, adventitia, contains fibroblasts, micro vessels, mast cells and nerve 
endings (Fig. 1.2A) (Chien, 2008; Libby, 2000; Zampetaki et al., 2010). The accumulation 
of lipids and fibrous material occurs mostly at branched areas, which are exposed to 
disturbed blood flow and ultimately leads to activation of pro-inflammatory signalling 
pathways (Chien, 2008). Lipid accumulation is also associated with higher apoptotic 
activity of ECs, reduced eNOS production, increased ROS production and responsible for 
increased permeability of ECs, which eventually leads to endothelial dysfunction and 
atherosclerosis (Zampetaki et al., 2010). Atherosclerotic lesion development starts with 
accumulation of monocytes into intima due to endothelial dysfunction.   
1.3.1 Stages of Atherosclerosis  
Atherosclerosis can be divided into following stages  
1. Endothelial dysfunction 
2. Migration and maturation of monocytes 
3. Plaque formation 
4. Thrombosis 
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Figure 1.2. Stages of Atherosclerosis. A. The innermost layer of artery is lined by ECs, which maintain the homeostatic 
balance between blood and artery. Middle layer consists mainly of SMCs, while the outer most layer contains nerve cell 
endings, fibroblast cells and mast cells. B. Inflammatory response leads to activation of ECs, which primes binding of 
monocytes to ECs, and their migration into intima. Inside intima, monocytes mature into macrophages, take up lipid 
molecules, and form foam cells. C. SMCs along with collagen fibers migrate to intima and make thick fibrous cap. Lipid 
molecules accumulate in centre of the plaque and form lipid core. D. Plaque cap ruptures due to disturbed blood flow, 
which triggers the immune response, and a thrombus is formed. Thrombus can block the artery partially or completely. 
(Figure published by Libby et al., 2011). 
 
1.3.1.1 Endothelial Dysfunction  
Endothelium is important to maintain homeostatic balance between blood and tissues (Fig. 
1.2A) (Chien, 2008; Zampetaki et al., 2010). Different environmental factors and signalling 
pathways are involved in protection and activation of ECs. Increased levels of 
homocysteine, LDL, micro-organisms, smoking and diabetes are considered as triggering 
factors of ECs dysfunction (Hadi et al., 2005; Higashi et al., 2012; Hueso et al., 2017; 
Messner and Bernhard, 2014). Cytokines like interleukin-1β and tumor necrosis factor α 
(TNF-α) are responsible for the initiation of ECs dysfunction by activating nuclear 
transcription factor κB (NF-κB) and protein kinase C pathways (Brown et al., 2014; Xiao et 
al., 2014). NF-κB is a key regulator of inflammation during atherosclerosis (Brown et al., 
2014). Activation of NF-κB leads to translocation of NF-κB from cytoplasm to the nucleus, 
which initiates transcription of downstream target genes including cytokines, chemokines 
and adhesion molecules like E-Selectin (SELE) and Vascular Cell Adhesion Molecule 1 
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(VCAM-1) (Gerhardt and Ley, 2015). ECs express adhesion molecules on their surface, 
which starts interacting with different blood cells like monocytes.  
1.3.1.2 Migration and maturation of Monocytes  
Migration of monocytes into intima is a multistep process that involves capturing of 
monocytes on activated ECs, slow rolling on the surface of ECs, firm binding to ECs and 
then migration into intima (Gerhardt and Ley, 2015). SELE mediates the capturing and 
slow rolling of monocyte and T-cells on ECs, while VCAM-1 is responsible for firm adhesion 
of leukocytes on ECs, which facilitates its migration into intima (Fig. 1.2B) (Gerhardt and 
Ley, 2015; Libby, 2000). Migrated monocytes mature into macrophages, which fuse with 
lipoproteins to make foam cells (Gerhardt and Ley, 2015; Libby, 2000).  
1.3.1.3 Plaque Formation  
Foam cells accumulate to make a lipid core of lesion. SMCs migrate from tunica media to 
intima and accumulate in lesions along with cellular and ECM like collagen, proteoglycans, 
and elastin and form thick fibrous cap (Gerhardt and Ley, 2015; Libby, 2000; Xiao et al., 
2014). The lesion protected by this thick fibrous cap is referred as atheroma or 
atherosclerotic plaque. Central lipid core of plaque, known as necrotic core, consists mainly 
of lipid molecules and cholesterol crystals (Fig. 1.2C) (Libby, 2000).  
1.3.1.4 Thrombosis  
Atherosclerotic plaques are of two types stable and unstable, based on their composition 
(Falk, 1992). Stable plaques are rich in ECM and SMCs and have thick stable cap. While 
unstable plaques are rich in soft extracellular lipids and highly infiltrated with foam cells 
leading to be more prone to rupture (Falk, 1992). Fibrous cap of unstable plaques ruptures 
due to physical abrasion from blood flow and activates acute thrombosis response that can 
lead to blood coagulation and thrombus formation (Fig. 1.2D). Thrombus can extend 
,restrict the lumen of the artery, and can cause further complications like angina, 
myocardial infarction, dysrhythmia and sudden cardiac arrest (Libby, 2000). 
Atherosclerosis reduces the normal blood flow, which can cause cardiac arrest and death. 
1.3.2 Signalling Pathways and transcription factors involved in Atherosclerosis 
Atherosclerosis is categorized as an inflammatory disease. Inflammation is the important 
step in initiation and progression of plaque formation (Conti and Shaik-Dasthagirisaeb, 
2015). Multiple signalling pathways have been identified as regulators of inflammation such 
as mitogen activated protein kinases (MAPKs), signal transducer activator of transcription 
    Introduction 
9 
 
(STAT), Janus-Kinase (JAK) and NF-κB (Montecucco et al., 2012; von der Thusen et al., 
2003). Among these signalling pathways, NF-κB is the main signalling pathway of 
inflammation (Hajra et al., 2000; Xiao et al., 2014).  
Figure 1.3. NF-κB Signalling pathway. NF-κB heterodimer (RelA and p50) is present in cytoplasm bound with IκB-α in 
an inactive state. When there is an inflammatory signal, IKK is activated and phosphorylates the IκBα, which is then 
degraded by the proteasome assembly. The activated NF-κB dimer migrates into the nucleus and binds to chromatin 
and initiates the transcription of inflammatory markers (E-Selectin, VCAM-I, ICAM-I, IL6, IL8). Adhesion molecules 
(VCAM-I, ICAM-I) are expressed on activated ECs and binds to monocytes. 
 
Activation of NF-κB pathway is reported in multiple inflammatory diseases like Rheumatoid 
arthritis, atherosclerosis, multiple sclerosis, asthma and inflammatory bowel disease (Tak 
and Firestein, 2001). NF-κB is a heterodimer consisting of p50 and p65 (RelA) subunits. In 
resting state ECs, NF-κB binds to its inhibitor (IκB-α), which keeps NF-κB in an inactive 
form (Tanaka and Iino, 2016; Xiao et al., 2014). Central step of NF-κB cascade is liberation 
of NF-κB from IκB-α. Inflammatory mediators like TNF-α, lipopolysaccharides (LPS) and 
Interleukin-1 (IL-1) binds to toll like receptors (TL4, TL2) on plasma membrane and 
activates IκB-Kinase (IKK) (Monaco and Paleolog, 2004). IKK phosphorylates IKB-α, which 
is subsequently ubiquitinated and degraded by proteasome assembly, and liberates NF-
κB for nuclear translocation (Monaco and Paleolog, 2004; Xiao et al., 2014). Inside the 
nucleus, NF-κB interacts with different chromatin modifiers (Histone deacetylases - 
HDACs, p300, BRD4), transcription factors (c-Myc, p53) and binds to enhancer regions of 
approximately 400 genes to induce their expression (Fig. 1.3) (Tanaka and Iino, 2016). 
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Multiple pro-inflammatory genes such as cytokines Interleukin 6 and 8 (IL6, IL8), TNF-α 
and adhesion molecules like SELE, Intercellular Adhesion Molecule 1 (ICAM-1), VCAM-1, 
which contribute for progression of inflammation and ECs dysfunction are all activated via 
NF-κB signalling pathway (Tanaka and Iino, 2016; Xiao et al., 2014). Among the regulatory 
partners of NF-κB, Bromodomain containing protein 4 (BRD4), a chromatin modifier has 
been recently highlighted more due to its important role during inflammation and in 
atherosclerosis (Picaud et al., 2013; Xu and Vakoc, 2014b). 
1.3.3 Role of BRD4 in atherosclerosis  
NF-κB interacting partners include different transcription factors and chromatin modifiers 
including BRD4 (Tanaka and Iino, 2016). BRD4, an epigenetic regulator, is a member of 
BET (Bromodomain and extra terminal domain) tandem bromodomain containing family. 
BET family members contain two N-terminal bromodomains, Bromodomain 1 (BD1) and 
Bromodomain 2 (BD2) and an Extra terminal (ET) domain (Najafova et al., 2017). BRD4 is 
known for its role in multiple cellular activities like inflammation, DNA damage repair, 
spermatogenesis, and cell cycle (Devaiah et al., 2016; Devaiah et al., 2012; Najafova et 
al., 2017). It is also involved in transcription of oncogenes (Crowe et al., 2016; Najafova et 
al., 2017). BRD4 has both histone acetyl transferase (HAT) and kinase activity (Devaiah et 
al., 2016; Devaiah et al., 2012). BRD4 recognizes and binds to acetylated lysine residues 
of histone proteins, H3 (H3K14 - histone 3 lysine 14) and H4 (H4K5 - histone 4 lysine 5 or 









Figure 1.4. Binding of BRD4 on chromatin and acting as HAT and Kinase. BRD4 protein binds to the acetylated 
chromatin and acetylates histones, leading to DNA-Histone disassembly and opening of chromatin. BRD4 recruits 
positive transcription elongation factor (P-TEFb) and RNA polymerase 2. BRD4 also acts as atypical kinase and 
phosphorylates CTD of RNA-Pol II to initiate transcription of target genes (Figure is published by Devaiah et al., 2016). 
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After binding to chromatin, BRD4 acetylates the core of histones at H3K122 residue and 
leads to nucleosome (histone-DNA complex) disassembly (Fig. 1.4), followed by 
recruitment of RNA Polymerase II (RNA Pol-II) (Devaiah et al., 2016). Then C-terminal end 
of BRD4 protein recruits positive transcription elongation factor (P-TEFB) (Crowe et al., 
2016; Devaiah et al., 2012). It has been reported that BRD4 phosphorylates the Serine 
residue at position 2 (Ser2) of Carboxy-terminal domain (CTD) of RNA Pol-II ensuring 
proper transcriptional initiation and elongation (Fig. 1.4) (Crowe et al., 2016; Devaiah et al., 
2012). 
Among the BET protein family members, BRD4 has higher expression in ECs than other 
BET proteins (Huang et al., 2016). There are two naturally existing splice variants/isoforms 
of BRD4 known as BRD4 Long (BRD4-L) and BRD4 short (BRD4-S) (Alsarraj et al., 2013; 
Alsarraj et al., 2011; Crawford et al., 2008). Both BRD4-L and BRD4-S proteins share the 
same N-terminal region except for last three amino acids, while the C terminal domain is 
absent from BRD4-S isoform (Fig. 1.5) (Chiang, 2009). BRD4 isoforms have been reported 
to act antagonistically in breast cancer progression, where the BRD4-L isoform reduces 
cancer metastasis, while the BRD4-S enhances the cancer metastasis (Alsarraj et al., 
2013). Moreover, BRD4-S isoform is overexpressed in colon cancer cell lines (Alsarraj et 
al., 2011). 
Figure 1.5. Human BRD4 protein isoforms structure. The long isoform of human BRD4 (hBRD4-L) is 1362 amino 
acid long (152kDa), while the short isoform of human BRD4 (hBRD4-S) is 722 amino acid long (80kDa). Both isoforms 
share similarity in structure concerning bromodomain I (BDI), bromodomain II (BDII) and an extra terminal domain (ET). 
However, the long isoform has extra C-terminal region (CTM) which is absent in short isoform.  
 
The evidence that BRD4 has influence on inflammatory response, specifically in 
atherosclerosis, came up in 2013. In this year, two independent studies revealed that BRD4 
was inhibited by a chemical compound, RVX-208, that was already tested for treatment of 
atherosclerosis by enhancing HDL components APO-A1, but whose exact molecular target 
till then remained unclear (Picaud et al., 2013; Xu and Vakoc, 2014b). RVX 208 is in clinical 
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trials for treatment of diseases like atherosclerosis, Diabetes, Alzheimer’s disease, and 
chronic kidney disease (Drugs.R.D, 2011; McLure et al., 2013; Vidler et al., 2013).   
After identifying BRD4 as a target of RVX208, much research was done to identify the 
exact contribution of BRD4 to atherosclerosis as well as to other inflammatory diseases. In 
quiescent ECs, BRD4 is known to interact with super enhancers (SEs) of genes that 
encode for proteins with basal cellular functions (Fig. 1.6). As described above, TNF-α 
mediated inflammatory stimuli results in the translocation of the NF-kB from cytoplasm to 
nucleus, which enhances the transcription of pro-inflammatory genes (Brown et al., 2014). 
Recent studies have uncovered that upon activation of NF-κB, BRD4 redistributes on 
chromatin from SEs of resting state genes to SEs of pro-inflammatory genes along with 
NF-κB (Drugs.R.D, 2011; McLure et al., 2013; Xu and Vakoc, 2014b). BRD4 interacts with 
acetylated Lysine residue (Lysine-310) of the RelA subunit of NF-kB (Huang et al., 2009). 
NF-κB and BRD4 have been reported to initiate an inflammatory response through up 
regulation of adhesion molecules and inflammatory cytokines (Fig. 1.6). Chromatin 
immunoprecipitation (ChIP) with massively parallel DNA sequencing (ChIP-seq) studies on 
ECs reported that SEs and promoter regions of 271 genes were enriched for RelA and 
BRD4 after inflammatory stimuli including SELE and VCAM1 (Brown et al., 2014; Xu and 
Vakoc, 2014b). 
 
Figure 1.6. Redistribution of BRD4 on chromatin during Inflammatory stimulus. I  in normal resting state ECs, 
BRD4 binds to SEs of resting state genes. II  During inflammatory state, BRD4 redistributes on chromatin and bind to 
SEs of pro-inflammatory genes along with NF-κB. (Figure published by Lou et al., 2014). 
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1.4 Cardiac Hypertrophy 
Cardiac hypertrophy is characterised by thickening and enlargement of heart muscles and 
shortening of ventricular chambers (Tardiff, 2006). Cardiac hypertrophy occurs due to 
inflammation and cardiomyocyte growth exceeding the capacity of capillaries to sufficiently 
supply nutrients and oxygen thus, leading to cardiac hypoxia and cardiomyocytes death. 
Furthermore, deposition of ECM and fibrosis leads to reduced blood pumping ability of 
heart (Shimizu and Minamino, 2016; Tardiff, 2006). There are two types of cardiac 
hypertrophy namely physiological and pathological hypertrophy, which are developed due 
to extra work load on heart (Tardiff, 2006). Physiological hypertrophy develops in response 
to pregnancy and excessive exercise, in which cardiac function is enhanced to fulfil the 
energy demand (Shimizu and Minamino, 2016). Pathological hypertrophy is characterised 
by myocardial dysfunction, change in sarcomeric structure, hypertrophic and fibrotic 
ventricle (Fig. 1.7) (Samak et al., 2016).  
                
Figure 1.7. The structure of a normal and cardiac hypertrophy heart. The structure of a normal heart (left) with a 
normal left ventricular size is shown. The structure of a left ventricular hypertrophic heart (right) showing reduced size of 
ventricular chamber due to increased fibrosis, increased size of cardiomyocytes and deposition of ECM. (Figure 
published by Mayo foundation for medical education and research https://www.mayoclinic.org/diseases-
conditions/hypertrophic-cardiomyopathy/symptoms-causes/syc-20350198 ). 
 
Multiple pathological conditions such as hypertension, valvular defects, ischaemia, 
coronary artery disease and diabetes, which increase the energy demand are responsible 
for the development of cardiac hypertrophy (Heineke and Molkentin, 2006). Initially, cardiac 
hypertrophy is a compensatory mechanism in response to increased work demand due to 
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mechanical and biochemical stress. During this phase, cardiomyocytes become enlarge 
and increase protein synthesis along with increase in cardiac fibroblasts proliferation 
(Heineke and Molkentin, 2006). Cardiac fibroblasts, under stress conditions, change their 
morphology between fibroblast and SMCs and are known as myofibroblasts (Manabe et 
al., 2002). Myofibroblast cells produce inflammatory chemokines, cytokines and play a 
significant role in the development of inflammation in hypertrophic heart (Manabe et al., 
2002). Prolonged hypertrophy results in cardiac cell death and leads to fibrosis, a condition 
in which collagen fibres deposits in ventricular chambers, stiffens the ventricles and 
reduced the contraction and relaxation of heart (Carreno et al., 2006; Manabe et al., 2002). 
Increased fibrosis leads to reduced oxygen diffusion, which create hypoxic environment 
resulting in cardiac cell death (Manabe et al., 2002). Stiffness of cardiac tissues and 
apoptotic conditions leads to impaired cardiac functions (Talman and Ruskoaho, 2016).  
1.4.1 Signalling Pathways in Cardiac Hypertrophy 
Multiple proteins and signalling pathways are known to act as stimulus for cardiac 
hypertrophy. Activated signalling pathways in physiological and pathological hypertrophy 
are different. In physiological hypertrophy, fibroblast growth factors (FGF), Ang II, insulin 
growth factors (IGF) and transforming growth factor β (TGFβ) activate tyrosine kinase 
receptors, which further on initiate the phosphoinositol-3-kinase (PI3K) and mammalian 
target of rapamycin (mTOR) signalling pathways (Fig. 1.8) (Samak et al., 2016). The 
activation of these signalling pathways leads to increased protein synthesis to compensate 
work load (Samak et al., 2016).  
On the other hand, in pathological hypertrophy activated signalling pathways include 
MAPKs and JAK, which activate the transcription of maladaptive genes responsible for 
hypertrophic growth (Carreno et al., 2006; Samak et al., 2016). G-protein-coupled 
receptors (GPCRs) are also activated in pathological hypertrophy through Ang-II, ET-I 
(Carreno et al., 2006; Samak et al., 2016). GPCRs activate multiple downstream 
transcription factors, specifically NF-κB and nuclear factor of activated T cells (NFAT) (Fig. 
1.8) (Samak et al., 2016). GPCRs activate voltage-gated calcium ion channels, which leads 
to elevated levels of calcium ions (Ca+2) inside cardiomyocytes (Carreno et al., 2006; 
Samak et al., 2016). Increased Ca+2 levels are detected by calmodulin (Cam), which leads 
to dephosphorylation and nuclear translocation of NFAT via activation of calcineurin A and 
B (CnA, CnB) (Fig. 1.8) (Samak et al., 2016).  





Figure 1.8. Signalling pathways in Cardiac hypertrophy. PI3K and mTOR signalling pathways are activated in 
physiological hypertrophy while MAPKs, JNK, NFAT and NF-κB are involved in the development of pathological cardiac 
hypertrophy. (Figure published by Samak et al., 2016) 
 
ROS also contributes to cardiac hypertrophy by inducing apoptosis and activating NF-κB 
signalling pathway (Fig. 1.8) (Samak et al., 2016). Activation of NF-κB signalling pathway 
and inflammatory cytokines expression, such as IL6, TNF-α and IL-1β, is a hallmark of 
hypertrophy (Carreno et al., 2006; Samak et al., 2016). The role of NF-κB signalling 
pathway is not clearly understood, however it is known that it enhances the infiltration of 
inflammatory cells such as macrophages and T-cells during fibrosis (Samak et al., 2016). 
Among the targets of NF-κB signalling pathway, Protein Tyrosine Phosphatase 1B 
(PTP1B) is a protein, reported to have higher expression during inflammation (Zabolotny 
et al., 2008).  
 
 




Protein kinases, which are responsible for phosphorylations at serine, tyrosine, threonine, 
and lysine residues, constitute one of the largest enzyme family encoded by human 
genome (Manning et al., 2002). Tyrosine phosphorylation is required for activation of 
receptor tyrosine kinases (RTKs), while protein tyrosine phosphatases (PTPs) are negative 
regulators of this activation. PTPs were first identified in 1988 when, PTP1B was purified 
from human placenta (Tonks et al., 1988). The PTP family of enzymes have four classes, 
classes I, II and III are known as cysteine-based PTPs, whereas class IV is known as 
aspartate-based PTPs (Alonso et al., 2004; Low et al., 2014). The class I PTPs are further 
divided into two subgroups namely transmembrane- or receptor-type PTPs and the 
intracellular PTPs (Barr, 2010). The first intracellular PTP to be purified and characterized 
was PTP1B (Tonks et al., 1988). 
PTP1B has three major domains on the basis of structure and function. The N-terminal 
catalytic domain is responsible for the phosphatase activity of the enzyme and two flanking 
Proline rich domains are responsible for protein-protein interactions, while the C-terminal 
ER targeting domain anchors the enzyme to endoplasmic reticulum (ER) (Fig. 1.9) (Yip et 
al., 2010).  
Figure 1.9. Domain architecture of PTP1B. The PTP1b enzyme has three major structural domains namely: Catalytic 
domain- the main central domain of the enzyme; Proline rich domain- responsible for binding of enzymes to its targets; 
and ER targeting domain- responsible for attachment of enzyme to ER.  
 
Expression of PTP1B is induced by TNF-α both in vivo and in vitro (Panzhinskiy et al., 
2013; Zabolotny et al., 2008). Multiple substrates of PTP1B have been identified and the 
prominent ones are insulin receptor tyrosine kinase, leptin signalling and vascular 
endothelial growth factor receptor (VEGFR) (Lanahan et al., 2014; Nakamura et al., 2008). 
Multiple studies have shown that Ptp1b-knockout (Ptp1b-KO) mice have higher insulin 
sensitivity, resistant to weight gain even when fed with high fat diet, and have lower level 
of triglycerides in blood, which is due to higher leptin sensitivity (Elchebly et al., 1999; 
Tamrakar et al., 2014). Neuronal Ptp1b KO mice are resistant to obesity and have higher 
 
    Introduction 
17 
 
physical activities, as compared to wild type mice, which become obese and slow, showing 
that leptin action is controlled by neuronal PTP1B (Bence et al., 2006). Pre-natal and post-
natal angiogenesis is a crucial biological process for the development of blood vessels and 
in wound healing (Ambler et al., 2001; Dormond et al., 2001; Isogai et al., 2001). VEGFR2, 
a tyrosine kinase receptor, is mainly involved in ECs migration during angiogenesis 
(Holderfield and Hughes, 2008; Lamalice et al., 2007). Interestingly, PTP1B is a negative 
regulator of VEGFR2 signalling in ECs (Lanahan et al., 2014; Nakamura et al., 2008). Both 
in vivo and in vitro studies showed that inhibition of PTP1B function enhances ECs 
migration and angiogenesis (Besnier et al., 2014; Lanahan et al., 2014).  
It has been confirmed that overexpression of PTP1B results in inhibition of VEGFR2 
phosphorylation, while endothelial-specific deletion of PTP1B (Endo.Ptp1b.KO) improves 
VEGF signal transduction (Lanahan et al., 2014; Nakamura et al., 2008). Genome wide 
gene expression analysis has confirmed the enhanced expression of PTP1B in case of 
high cardiac afterload (Toischer et al., 2010). Long term application of PTP1B inhibitor or 
short hairpin RNA (shRNA) mediated inhibition in mice improves angiogenesis, ECs 
function and reduces cardiac remodelling, making PTP1B as a promising new target to 
treat CVDs (Gomez et al., 2012).   
Previous studies used systemic pharmacological inhibition or genetic deletion of Ptp1b in 
mice model, which protects the mice from heart failure after MI and improves ECs 
dysfunction. However, this inhibition or deletion can affect other cell types (cardiomyocytes, 
fibroblasts) in cardiac remodelling. Therefore, role of ECs remained unclear. To overcome 
this problem, ECs specific Ptp1b KO (Endo.Ptp1b.KO) mice were generated (Gogiraju et 
al., 2016). These mice, upon cardiac overload by transverse aortic constriction (TAC), 
showed reduced oxidative stress, cardiac hypoxia, fibrosis, enhanced angiogenesis, which 
resulted in improved survival. In this regard, it is interesting to identify novel 
proteins/pathways, which are involved in PTP1B deficient hearts to device efficient 
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1.5 Aims of the study  
The present study is designed to better understand the role of BRD4 and its isoforms in 
ECs during inflammation by using in-vitro model of Human umbilical cord derived vascular 
endothelial cells (HUVECs). The aim is to investigate role of BRD4 isoforms in heart tissues 
of mice models of aging and cardiac hypertrophy. Moreover, we want to investigate role of 
BRD4 in monolayer integrity of ECs during inflammation. We also want to analyse PTP1B 
expression during inflammation and identify the possible mechanism responsible for cardio 
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2. Materials and Methods 
2.1 Cell Culture 
All in-vitro experiments were performed using primary Human Umbilical cord derived 
Vascular Endothelial Cells (HUVECs) under sterile conditions. HUVECs were purchased 
from Promo Cell and cultured using growth medium prepared by mixing Endothelial cells 
basal medium (Promo Cell) and Endothelial Cell Growth Medium Supplement Pack (Promo 
Cell), 1% Penicillin/Streptomycin (Sigma). Cells were cultured on 0.2% Gelatin coated 
flasks/plates at 37°C in a humidified incubator with 5% CO2. For trypsinisation, cells were 
washed with DDPBS (PAN-Biotechnologies) and incubated in Trypsin-EDTA (Gibco) at 
37°C for 3-5 min. Trypsin activity was inhibited with DMEM medium (PAN-Biotechnologies) 
containing 10% FCS (Gibco) and 1% Penicillin/Streptomycin. Trypsin was removed by 
centrifugation at 1000 x g for 5 min. Cells were resuspended in growth medium and 
transferred to a new flask. Cell counting was performed, when necessary, by using 
Neubaeur improved chamber. The cells which are at passages between 7 and 9 were used 
for all the experiments. 5 х 104 cells/cm2 were used for all treatments unless otherwise 
stated. 
 
2.2 Treatments  
2.2.1 TNF-α treatment 
Human recombinant TNF-α (Peprotech) stock solution (2.5 μg/ml) was prepared in 0.1% 
BSA solution. Cells were treated with 20 ng/ml of TNF-α for 2 hrs, then washed with DPBS 
before fixation or trypsinisation. 
2.2.2 JQ1 treatment  
5 mg of Bromodomain Inhibitor JQ1 (ApexBio technologies) was dissolved in 109.41 μl 
DMSO (Sigma) to prepare a stock solution of 100 μM. Cells were treated with 500 nM JQ1 
for 4 hrs or 12 hrs depending upon experimental set up. Control cells were treated with 
equal volume of DMSO, then washed with DPBS before fixation or trypsinisation. 
2.2.3 RVX208 treatment  
5 mg of Bromodomain inhibitor RVX208 (ApexBio technologies) was dissolved in 1 ml of 
DMSO (Sigma) to prepare a stock solution of 13.498 mM. Cells were treated with 50-, 100-
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, 150- and 200-μM RVX208 for 4 hrs or 30- and 60-μM 12 hrs depending upon experimental 
set up. Control cells were treated with equal volume of DMSO, then washed with DPBS 
before fixation or trypsinisation. 
2.2.4 Claramine treatment  
5 mg of PTP1B inhibitor Claramine trifluoroacetate salt (Sigma) was dissolved in 1 ml of 
water to prepare a stock solution of 8.49 mM. Cells were serum starved for 2 hrs in ECs 
medium in absence of serum followed by treatment with 10-, 50- and 100-μM of Claramine 
for 30 mins, then washed with DPBS before fixation or trypsinisation. 
 
2.3 Immunofluorescence staining of HUVECs   
Cells were grown on small cover slips coated with 0.2% Gelatin and treated, as indicated. 
After completion of the experiment, the culture media was removed, and cells were washed 
with DPBS. Cells were fixed with 4% PFA for 30 mins. followed by washing with DPBS 2 
times for 10 min each (2 X 10 min). Afterwards, blocking was done with 50 mM Ammonium 
Chloride (NH4Cl) for 10 min at room temperature (RT). Cells were washed (3 X 4 min) with 
permeabilization buffer (0.2% Triton X-100 (Sigma) in DPBS) followed by incubation at RT 
with anti NF-κB antibody (cell signalling) prepared at 1:100 dilutions in permeabilization 
buffer. After 1 hr of incubation, cells were again washed 3 X 4 min each with 
permeabilization buffer. Afterwards, cells were incubated with 1:300 diluted secondary 
antibody, anti-rabbit IgG conjugated with Alexa 488 (Life Technologies), for 1 hr at RT 
followed by washing again with permeabilization buffer (3 X 4 min) to remove excessive 
antibody. Finally, cells were washed twice with DPBS and mounted with 4`,6-Diamidino-
2Phenylindole, Dihydrochloride (DAPI) (Vector Laboratories). Fluorescent cells were 
visualised using Axiovert 200M confocal Microscopy (Carl Zeiss).  
 
2.4 RNA expression analysis  
2.4.1 RNA extraction from Cells/Tissues  
For total RNA extraction, Trizol (Invitrogen) was used according to manufacturer’s 
instructions. Briefly, HUVECs were treated, washed with DPBS twice and then harvested 
by trypsinization. 500 μl of Trizol reagent was added/ 10 cm2 and cells were homogenized 
by vortexing, and total RNA was precipitated using chloroform/isopropanol extraction 
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method (Rio et al., 2010). RNA was washed with 70% Ethanol and air dried, then dissolved 
in Diethylpyrocarbonate (DEPC) (Sigma) treated dH2O and stored at -80°C. RNA was 
quantified using NanoDrop 2000C (PeqLab, ThermoFisher Scientific). 
RNA extraction form mice heart tissues was done by pulverizing the tissue in liquid nitrogen 
using conventional mortar and pistol. Afterwards, pulverized tissues were dissolved in 
Trizol using a tissuelyser bead mill (Qiagen). The remaining RNA extraction protocol was 
as described above.   
2.4.2 cDNA synthesis 
cDNA was prepared by using SuperScript™ IV First-Strand Synthesis System (Invitrogen). 
DNase digestion was performed on total RNA before cDNA synthesis. Briefly, 2 μg of RNA 
ideally in 8 μl of DEPC water was incubated with 1 μl of Amplification grade DNase enzyme 
(Sigma) and 1 μl of 10x DNase reaction buffer (Sigma) for 15 min at RT. 1 μl of Stop 
solution (Sigma) was added to inhibit the reaction and heated at 70°C for 5 min. Then 1X 
Reverse Transcriptase buffer (Invitrogen), 0.5 μMol/L each dNTP (Roche), 13.3U M-MLV-
RT (Invitrogen) enzyme and 1 U/μl RNase inhibitor (Promega) and 0.15μM Primer p(dT)15 
for cDNA synthesis (Roche) were added and incubated at 42°C for 1 hr. Inactivation of 
enzymes was done by heating the reaction mix at 70°C for 10 min. cDNA was stored at -
20°C. 
2.4.3 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
Primers were designed by using online Primer 3 software. Details of primers used in this 
study are given in tables 2.1 and 2.2. qRT-PCR reaction mixture was prepared by mixing 
1 μl of 10 X PCR reaction buffer (Roche), 1 μl of DMSO (Sigma), 0.5 μl of 1:1000 dilutions 
of SYBR Green (sigma), 0.2 mmol of each dNTP (Roche), 0.15 U of Taq-Polymerase 
(produced In-house), 10pmol/μl of Forward and Reverse primers and 1μl of cDNA (1:10 
diluted), volume was made up to 20μl with H2O. PCR conditions to amplify cDNA were set 
as  
• Denaturation, 95°C for 2 min one cycle,  
• PCR-40 cycles  
➢ denaturation 95°C for 30 sec,  
➢ Annealing 56°C for 30 sec,  
➢ Extension 72°C for 30 sec.  
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• Acquisition temperature was different for each primer set (Table 2.1). 
PCR reaction were run and analysed using LightCycler 480 (Roche). Data was analysed 
with LightCycler 480 software SW 1.5.1 (Roche) and values were normalised to house-
keeping gene human/mice GAPDH/Gapdh and in case of isoform study BRD4-Total/Brd4-
total. Comparative Ct method (2-∆∆Ct) was used to measure relative fold change mRNA 
expression (Schmittgen and Livak, 2008).  
Table 2.1 Human mRNA expression primer list 
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Table 2.2 Mouse mRNA expression primer list 
  Gene name   Direction   Sequence 
 Product 
 Size (bp) 
 Acquisition  
 Temp (°C) 
  Gapdh 
  Forward   AGGTCGGTGTGAACGGATTTG 
  129 
   
  81 
  Reverse   TGTAGACCATGTAGTTGAGGTCA 
  Brd4-Common 
  Forward   AAGCCTGGAGATGACATCGT 
   148 
 
  81 
  Reverse   TTGCTGCCCCTGTTTCTTTC 
  Brd4-Long 
  Forward   AGCCAAGTCCTCAAGTGACA 
   107 
 
  81 
  Reverse   TCTCCTTCTCTGCATGCTCA 
  Brd4-Short 
  Forward   ACGTGATTGCTGGTTCTTCC 
   123 
 
  81 
  Reverse   CCGTGTCCAATGATTAGGCA 
 
2.5 Cell Viability Assay 
Cell viability assay for each experimental set was performed using trypan red cir dye 
exclusion assay. Briefly, cells were trypsinised and resuspended in 1 ml of HUVEC 
medium. 5 μl of resuspended cells were mixed with 20 μl of media and 25 μl of 0.5% trypan 
blue dye. Then, 10μl of mixture was loaded onto haemocytometer. Viable cells (colourless) 
and non-viable cells (blue coloured) were counted and percentage of viable cells was 
calculated. 
 
2.6 Protein Isolation 
HUVECs were grown and treated as described above. Cells were washed with DPBS and 
trypsinised. Cell pellets were resuspended by using lysis buffer (Cell Signalling) containing 
final concentration: 2 mM Tris/HCl, 15 mM NaCl, 0.1 mM Na2EDTA, 0.1 mM Egtazic acid 
(EGTA), 0.1% Triton X-100, 0.25 mM sodium pyrophosphate, 0.1 mM β-glycerophosphate, 
0.1 mM Sodium orthovanadate (Na3VO4), 0.1 μg/ml leupeptin and 1 mM 
Phenylmethylsulfonyl fluoride (PMSF), EDTA-free protease inhibitor cocktail (Sigma) and 
Phospho-stop phosphatase inhibitor (Sigma) were added freshly. Lysates were centrifuged 
at 13000rpm for 15min and clear supernatants (total proteins) were separated. Proteins 
quantification was done by Bradford method using protein reagent dye (Bio-Rad). 




2.7 Western blot 
Equal amounts of protein (35μg) were resolved on 4-12% Bis-Tris SDS-PAGE (sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis) gels (Thermofisher Scientific) together 
with molecular weight standards, Proteins were transferred onto nitrocellulose membrane 
of 0.4 μM pore size (Millipore) by using Trans-blot SD cell system (Bio-Rad) for one hour. 
To avoid non-specific binding, membranes were blocked in blocking buffer: 5% milk in Tris-
buffered saline, containing 50mM Tris-HCl, 200 mM NaCl and 0.1% Tween-20 (TBST). 
Blocked membranes were incubated overnight at 4°C with blocking buffer containing 
indicated primary antibodies against, anti-HSP70-antibody (Cells Signaling #4872) in 
1:1000 dilution, anti-BRD4-antibody (Abcam # ab84776) in 1:1000 dilution, anti-β-actin-
antibody (Sigma # A5316) in 1:10,000 dilution, anti-MIDKINE-antibody (Abcam #ab36038) 
in 1:500 dilution, anti-PTP1B-antibody (Cell Signaling #5311) in 1: 1000 dilution, anti-AKT-
antibody (Cell Signaling #9272) in 1:1000 dilution and anti-p-AKT (Ser 473)-antibody (Cell 
Signaling #9271) in 1:500 dilution. Next day, membranes were washed in blocking buffer 
for 3 times 15 min each followed by incubation with horseradish peroxidase-conjugated 
(HRP-conjugated) secondary antibody (Bio-Rad) in 1:10,000 dilution for 1hr at room 
temperature. Membranes were washed in blocking buffer 3 times, 15 min each followed by 
washing with DPBS. Protein bands were detected by using chemiluminescence detection 
method using Chemi-Doc (Bio-Rad). Protein bands were quantified by Image lab software 
and normalized to either HSP70 or β-actin. 
 
2.8 Trans-Endothelial/Epithelial Electrical Resistance (TEER) 
In order to analyse the intactness of HUVECs monolayer, TEER was measured across the 
monolayer as described previously (Callahan et al., 2004; Kazakoff et al., 1995; Man et al., 
2008). Briefly, HUVECs were plated on 0.4μM transwell inserts (Corning CoStar 
cooperation), coated with collagen, and plated cells at a density 1 x 105 cells/well at 
passage 4. Achievement of monolayer was confirmed by measuring the TEER across the 
monolayer. Experiments were performed only when TEER reached the reference value of 
>70Ω.cm2 as described previously (Callahan et al., 2004; Kazakoff et al., 1995; Man et al., 
2008; Srinivasan et al., 2015). Established monolayers were treated with DMSO (control) 
for 12 hrs, TNF-α for 12 hrs, RVX208/JQ1 for 12 hrs, pre-treatment with RVX208/JQ1 for 
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12 hrs followed by TNF-α for 12 hrs. TEER was measured after 1-, 3-, 6-, 12- and 24-hrs 
of treatments using the epithelial volt/Ohm meter (EVOM2). Values were normalized 
against the resistance of blank well coated with collagen and containing only medium.  
 
2.9 Statistical Analysis 
Statistical analysis of real time, western blot and TEER data was performed using 
GraphPad Prism 5 software. Three or more independent biological replicates of all 
experiments were analysed by analysis of variance (ANOVA) and were compared to 
control groups by using Bonferroni post-test. Statistical significance was analysed by using 
Student´s t-test. All results were plotted in graphs as mean and error bars represent ± 
standard error mean (SEM). Probability of less than 0.05 was considered significant (* 
p<0.05, ** p<0.01, *** p<0.001). 
 
2.10 Experimental animals 
2.10.1 Aging Mice 
Wild-type C57BL/6 mice (courtesy of Dr. Muzna Zahur, Viral Vector Lab, Department of 
Neurobiology, UMG) which were bred under sterile conditions and animals were sacrificed 
at the age of 1-, 3-, 6-, 8-, 12-, 15- and 18-months. Hearts were immediately frozen in liquid 
nitrogen.  
2.10.2 Hypertrophic Mice  
The generation and maintenance of inducible Endothelial cell-specific Ptp1b knock-out 
(Endo.Ptp1b.KO) and the corresponding control (Endo.Ptp1b.WT) mice were reported 
previously (Gogiraju et al., 2016). Likewise, the transverse aortic constriction (TAC) or 
SHAM surgery on 10-12 week old female mice (Endo.Ptp1b.KO and Endo.Ptp1b.WT) was 
reported previously (Gogiraju et al., 2016). Briefly, mice with loxP flanked Ptp1b allele 
(Ptp1bfl/fl) were bred either with Wild type mice or with transgenic mice expressing a fusion 
protein of Cre recombinase-estrogen receptor under the control of endothelial receptor 
tyrosine kinase promoter (Tie2.ERT2.Cre). The off-spring with desired genotype were then 
fed with Tamoxifen diet to induce Cre recombinase activity. Afterwards, 10-12 weeks-old 
females with either KO or WT genotype were subjected to TAC or SHAM surgery. In TAC 
group, a band is placed around the aorta of mice to induce pressure on heart, while SHAM 
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(an experimental control) group also underwent surgery, however, aortic arch was exposed 
but no band was placed around the aorta. This strategy gave rise to four groups of animals 
namely: 1. Wild-type SHAM (WT-SHAM), 2. Wild-type TAC (WT-TAC), 3. Endothelial-
specific Ptp1b knockout SHAM (KO-SHAM), and 4. Endothelial-specific Ptp1b knockout 
TAC (KO-TAC). After 20 weeks of TAC/SHAM surgery, five independent animals were 
taken from each group as biological replicates and whole heart tissue lysates were 
prepared in the presence of protease and phosphatase inhibitors. Afterwards, 50 μg of 
proteins were tryptic digested and the resulting peptides were subjected to liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) analysis. 
 
2.11 Global Proteome analysis 
2.11.1 In-solution digestion  
We performed the in-solution digestion of total proteins essentially as described previously 
(Leon et al., 2013), with minor modifications. Equal amounts of proteins (50 μg) from each 
animal were precipitated with 5 volumes of ice cold 100% acetone. Pellets were washed 
with 1 ml of ice cold 80% ethanol (Waters), dried and resuspended in 0.1% Rapigest 
(Waters) solution (Rapigest prepared in 25 mM ammonium bicarbonate solution). Proteins 
were then reduced using dithiothreitol (DTT) and alkylated with iodoacetamide (IAA). 
Trypsin concentration of 0.1 μg/μl (Promega) was used at 1:40 ratio to Protein: Trypsin 
(For 1mg protein 25 μg trypsin) to digest the protein. Proteins were digested overnight at 
37° C with constant shaking. After overnight incubation, formic acid was added to reduce 
the pH and to stop the trypsin reaction as well as to degrade Rapigest. Samples were 
centrifuged at 13000 rpm for 5 min to pellet down undigested proteins and degraded 
Rapigest. Supernatants were dried in the speed vacuum concentrator and processed for 
mass spectrometry analysis. 
2.11.2 LC-MS/MS Analysis  
For mass spectrometric analysis, samples were reconstituted in 2% acetonitrile/0.1% 
formic acid (v:v) and were analysed as described previously (Khan et al., 2016). Briefly, 
reconstituted samples were analysed at Q-Exactive hybrid quadrupole mass spectrometer 
(ThermoFisher Scientific) by using Excallibur 2.4 software. 70,000 full width at half 
maximum (FWHM) resolution settings were used to acquire MS scan across 350-1600m/z. 
Peptides were selected on basis of following criteria: charge state 2, or higher, up to 12 
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most abundant peptide, intensity threshold of >2*10-4. Followed by isolation at 2.0 FWHM 
width, fragmentation was done with nitrogen at 25% collision energy. In order to record the 
resulted product ion spectra resolution setting was 17,5000 FWHM. Three technical 
replicates per sample were acquired. 
2.11.3 Bioinformatic analysis of mass spectrometry data 
Peak lists were extracted with Raw2MSMS software in data independent acquisition (DIA) 
model and the obtained mass spec data was processed using Sequential Window 
Acquisition of all THeoretical fragment ion spectra (SWATH) analysis. Difference of 
expression between the groups was observed by Principle Component Analysis (PCA) 
using MarkerView Software 1.2.1.1 (AB SCIEX). In order to perform cluster analysis, we 
used Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database to 
analyse functional annotation of differentially expressed proteins.  
2.11.4 Welch’s t-test based analysis  
After validation of different clusters in PCA, data was further analysed by Welch’s t-test to 
generate lists of differentially expressed proteins (significance level p< 0.05) between all 
groups. Comparison was done first between WT-SHAM and KO-SHAM groups and then 
between WT-TAC and KO-TAC groups. Detailed analysis of proteomic data set with 
Welch’s t-test generated lists of upregulated and downregulated proteins in all groups. 
Volcano plots were generated by using -Log10 of p values (Welch’s t test), which were 
associated with individual proteins, against Log2 of fold change in abundance between the 
WT-SHAM and KO-SHAM, WT-SHAM and WT-TAC, KO-SHAM and KO-TAC, WT-TAC 
and KO-TAC.  
2.11.5 Ingenuity Pathway analysis (IPA) 
In order to analyse the proteome data with reference to functions of proteins, pathways 
involved, upstream regulators, downstream effectors, we decided to use Ingenuity 
Pathway analysis (IPA- Qiagen) in collaboration with Prof. Tuula Anneli Nyman, University 
of Oslo. The data was uploaded to IPA after calculating p-values and fold change using 
Perseus software. Direct and indirect relationship between the differentially regulated 
proteins were analysed and supported by previously reported experimentally observed 
data from human and mice studies. We considered proteins with a p values <0.05 and a 
fold change cut-off value of 1.5 as significant and generated the lists of top canonical 
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pathways, differentially abundant proteins and potential upstream regulators based on 
statistical measurement of differential expression based on the statistical effect size, log2 
ratio, and the P value (Z-Score). 
 
2.12 Mitochondrial Functional Assay 
In order to analyse the effect of PTP1B inhibition on HUVECs mitochondrial function, we 
used mitochondrial ToxGloTM assay kit (Promega). Briefly, 1x104 cells/well were plated in 
96 well culture plates. Cells were allowed to adhere and grow over night. Next day, cells 
were treated as follows: 1. non-treated control, 2. Claramine 100μM (PTP1B inhibitor) 30 
min, 3. TNF-α only (1500/ml for 6hrs), 4. Pre-treatment with Claramine for 30 min followed 
by TNF-α treatment for 6hrs, 5. Sodium Azide 100μM for 3 hrs.  
After completion of treatments, cell membrane integrity was analysed via detection of dead 
cell protease activity. 5X cytotoxicity detection reagent was prepared by mixing 10 μl of 
fluorogenic peptide substrate (Promega) with 2 ml of assay buffer (Promega). 20 μl of 
cytotoxic detection reagent was added and incubated at 37°C for 30 min. Cytotoxic 
detection reagent analyse membrane integrity and give fluorescence while interacting with 
necrosis associated protease. Fluorescence was measured with Victor multilabel counter 
(Wallac) at 485nmEx/520–530nmEm. Average of measured values of non-treated controls 
were subtracted from average of all treatments and percentage response of each test was 
calculated.  
Next, 2X ATP detection reagent was prepared by mixing 10 ml of ATP detection buffer 
containing ATPase inhibitors and Luciferase (Promega) with lyophilised ATP detection 
substrate, luciferin (Promega). 100 μl of ATP detection reagent was added to lyse the cells. 
ATP generates the luminescent signal which was measured with Victor multilabel counter 
(Wallac). Average of measured values of non- treated controls were subtracted from 
average of treatments and percentage response of each test was measured. To minimise 
the ATP production from glycolysis, all treatments were done in DMEM containing 







3.1 Establishment of in-vitro inflammatory model using HUVECs 
In order to establish the in-vitro inflammatory model, HUVECs were treated with or without 
(control) 20ng/ml TNF-α for 2 hrs. Afterwards, cells were fixed in 4% PFA, stained with 
anti-NF-κB antibody and analysed for cellular localisation of NF-κB. As expected, NF-κB 
was localised in cytoplasm of control cells, however, it translocated inside the nucleus in 
TNF-α treated cells (Fig. 3.1A). It is known, that upon activation by inflammatory stimuli, 
NF-κB binds to Super Enhancers (SEs) of pro-inflammatory genes regulatory regions and 
turn-on the transcription of pro-inflammatory genes like VCAM-I, SELE, IL6 and IL8. Hence, 
we performed mRNA expression analysis for VCAM-I and SELE, two well-known markers 
of inflammation, and found significantly induced expression of them in TNF-α treated cells 
as compared to control cells (Fig. 3.1B). These results confirm the successful 
establishment of in-vitro inflammatory phenotype in HUVECs. 
 
Figure 3.1. Establishment of inflammatory phenotype in HUVECs. A, Immunofluorescence images showing control 
(-) and TNF-α treated (+) HUVECs which were stained with anti-NF-κB antibody (red) and nuclei were counter-stained 
with DAPI (blue). B, bar graph showing relative mRNA levels of VCAM-I and SELE after normalization to house-keeping 
gene GAPDH, in control and TNF-α treated cells. Values are mean ± SEM of three biological replicates and asterisks 
indicate statistical significance of *** p< 0.001.  
 
After establishment of in-vitro inflammatory model, we decided to analyse the effect of 
BRD4 inhibition on HUVECs with and without inflammatory stimuli. We wanted to analyse, 





3.2 Role of BRD4 during inflammation  
It is recently reported that BRD4 interacts with NF-κB and the resulted complex binds to 
SEs of pro-inflammatory gene regulatory regions during inflammatory response (Brown et 
al., 2014; Xu and Vakoc, 2014a). Therefore, it is interesting to analyse whether BRD4 
inhibition has any significant effect on inflammatory response. Towards this end, we 
comparatively studied two small molecule inhibitors of BRD4, namely JQ1 and RVX208. 
3.2.1 BRD4 inhibition using JQ1 inhibitor 
The small molecule thienotriazolodiazepine, widely known as JQ1, binds to bromodomains 
of BET family proteins BRD2, BRD3, BRD4 and BRDT, and inhibits their activity (Bid and 
Kerk, 2016). Among the BET family members, BRD4 is highly expressed in HUVECs; 
hence the results obtained with JQ1 might be directly attributable to BRD4 inhibition in 
these cells (Huang et al., 2016). To establish the concentration of JQ1 required to efficiently 
inhibit the BRD4 function, we treated HUVECs with different concentrations of JQ1 (50 nM 
to 1 μM) for 4 hrs followed by 2 hrs of TNF-α treatment. Thereafter, cells were harvested 
and analysed for the expression levels of pro-inflammatory marker VCAM-I. Our analysis 
indicated that treatment with 500 nM of JQ1 was more effective in suppressing pro-
inflammatory marker expression in our system (Fig. 3.2A). As these preliminary results are 
in agreement with the literature (Brown et al., 2014), we decided to use 500 nM of JQ1 in 
all our further experiments, unless otherwise stated.  
Next, we designed an experimental set-up in which HUVECs were treated in four groups:- 
1: Control - cells were treated with DMSO for 4 hrs, 2: TNF-α-only - cells were treated 
with DMSO for 4 hrs followed by TNF-α for 2 hrs, 3: JQ1-only - cells were treated with JQ1 
for 4 hrs, and 4: JQ1+TNF-α - cells were treated with JQ1 for 4hrs followed by TNF-α for 
2 hrs. In order to check any possible cytotoxic effect of TNF-α and JQ1 treatments on 
HUVECs, we checked the viability of cells after treatments by using Trypan blue dye 
exclusion assay. These results showed that none of the treatments had any significant 
cytotoxic effect as compared to control cells (Fig. 3.2B). RNA expression analysis revealed 




markers, whereas TNF-α treated cells showed significantly higher expression of 
inflammatory markers (Fig. 3.2C).  
Figure 3.2. BRD4 inhibition using small molecule inhibitor JQ1. A, bar graph showing relative mRNA expression of 
VCAM-I after normalization to house-keeping gene GAPDH, in HUVECs treated with DMSO (control)-, TNF-α-only, JQ1-
only- (1 µM), and various concentrations of JQ1 (50-, 100-, 250-, 500 nM, and 1µM) followed by TNF-α treatment. B, bar 
graph showing viability of cells (% viability unit) after treated with TNF-α-only, JQ1-only and JQ1+TNF-α. C, bar graph 
showing relative mRNA levels of VCAM-I and SELE after normalization to house-keeping gene GAPDH, in DMSO 
(control), TNF-α treatment, JQ1-only treatment and JQ1 followed by TNF-α treatment. Values in A and C are mean ± 
SEM of three biological replicates and asterisks indicate statistical significance of *** p< 0.001, and ** p<0.01. D, 
Immunofluorescence images of HUVECs treated with DMSO (control)- , TNF-α-only- , JQ1-only and JQ1+TNF-α were 







Interestingly, pre-treatment with JQ1 significantly blocked the expression of pro-
inflammatory markers VCAM-I and SELE by 20-fold and 9.5-fold, respectively, as 
compared to TNF-α-only treated cells (Fig. 3.2C). These results indicate successful 
inhibition of BRD4 function, which results in blocking of its binding to SEs of pro-
inflammatory genes and subsequent inhibition of their expression.  
As a next step, we analysed NF-κB localisation in above mentioned treatments. As 
expected, NF-κB is present in the cytoplasm of control and JQ1-only treated cells, whereas 
it translocated into the nucleus in TNF-α treated cells. Notably, we found that JQ1 pre-
treatment did not affect the nuclear translocation of NF-κB (Fig. 3.2D). 
Collectively, these results indicate that JQ1 inhibits the function of BRD4 in HUVECs and 
thereby alleviates the inflammatory phenotype. Although JQ1 has been used in almost all 
BRD4 inhibition studies, its non-specificity to BRD family proteins and short half-life makes 
it unsuitable for clinical use (Wadhwa and Nicolaides, 2016). Recent studies identified 
RVX208 as another BRD4 inhibitor, which covalently binds to BD2-domain of BRD4 
(Picaud et al., 2013; Wadhwa and Nicolaides, 2016). Interestingly, RVX208, whose 
molecular target was not known until recently, was already used in clinical trials for 
treatment of different diseases like atherosclerosis, diabetes, Alzheimer’s disease, and 
chronic kidney disease (Nikolic et al., 2015; Picaud et al., 2013). Hence, we comparatively 
studied the efficiency and effectivity of BRD4 inhibition using JQ1 and RVX208 in our 
inflammatory model. 
3.2.2 BRD4 inhibition using RVX208 inhibitor 
To establish the concentration of RVX208 required to efficiently inhibit the BRD4 function, 
we treated HUVECs with different concentrations of RVX208 (50-, 100-, 150-, and 200 μM) 
for 4 hrs followed by 2 hrs of TNF-α treatment as we established for JQ1 experiments. 
Thereafter, cells were harvested and analysed for the expression level of pro-inflammatory 
marker SELE. This analysis showed no expression reduction of SELE in TNF-α treated 
cells (Fig. 3.3A), indicating that RVX208 probably could not inhibit BRD4 function, even at 
higher concentration, and after 4 hrs of treatment. Hence, we decided to use time 
dependent strategy to identify the time and concentration of RVX208 required to inhibit 
BRD4 function. For this reason, we treated the cells with 30 μM and 60 μM of RVX208 for 
12-, 24-, and 48-hrs followed by treatment with TNF-α. In order to check any possible 




cells after treatments by using Trypan blue dye exclusion assay. Our results showed that 
cell viability after 12 hrs of DMSO and RVX208 treatment was better than 24 hrs and 48 
hrs (Fig. 3.3B). 
 
Figure 3.3. Optimization of RVX208 treatment for inhibition of BRD4 function. A, bar graph showing relative mRNA 
levels of SELE after normalisation to house-keeping gene GAPDH in DMSO (control), TNF-α treatment, RVX208 (50-, 
100-, 150-, and 200 μM) followed by TNF-α treatment. B, bar graph shows percentage cell viability count in three different 
sets 1: 12 hrs set. DMSO (control) 12 hrs, TNF-α-only 12 hrs, RVX208-only 12 hrs, RVX208 (30 and 60 μM) 12 hrs 
followed by TNF-α 12 hrs. 2: 24 hrs set. DMSO (control) 24 hrs, TNF-α-only 12 hrs, RVX208-only 24 hrs, RVX208 (30 





hrs, RVX208 (30 and 60 μM) 48 hrs followed by TNF-α 12 hrs. C, bar graph showing relative mRNA levels of SELE after 
normalisation to house-keeping gene GAPDH, in DMSO control, TNF-α-only, RVX208-only 30 μM and 60 μM (12 hrs to 
48 hrs), and RVX208 (30 μM and 60 μM) followed by TNF-α treatment. D. bar graph showing relative mRNA levels of 
SELE after normalisation to house-keeping gene GAPDH, in DMSO control, TNF-α-only, JQ1-only for 12 hrs, JQ1 12 hrs 
followed by TNF-α treatment for 12 hrs. A,C, D, values are mean ± SEM of three biological replicates and asterisks 
indicate statistical significance of *** p< 0.001. 
 
RNA expression analysis indicated that the 12 hrs pre-treatment with RVX208 significantly 
reduces the expression of pro-inflammatory marker SELE by 4-fold, as compared to TNF-
α treatment (Fig. 3.3C). Based on these results, we decided to use 60 μM of RVX208 for 
12 hrs in all our further experiments, unless otherwise stated. As we wanted to perform the 
comparative studies on RVX208 and JQ1, we first established whether JQ1 could also be 
used at 500 nM for 12 hrs. We treated the cells with 500 nM of JQ1 for 12 hrs, TNF-α for 
12 hrs, and JQ1 for 12 hrs followed by TNF-α 12 hrs. Then we performed the RNA 
expression analysis and found that pre-treatment with JQ1 for 12 hrs could reduce the 
expression of pro-inflammatory marker SELE by 5-fold (Fig. 3.3D). 
After establishing both time and concentrations of RVX208 and JQ1 required to efficiently 
inhibit the inflammatory response, we designed the following experimental setup in which 
both RVX208 and JQ1 were compared simultaneously. 1: Control -cells were treated with 
DMSO for 12 hrs. 2: TNF-α-only - cells were treated with TNF-α for 12 hrs. 3: RVX/JQ1-
only - cells were treated with either RVX or JQ1 for 12 hrs. 4: RVX/JQ1+TNF-α - cells 
were pre-treated with either RVX or JQ1 for 12 hrs then with TNF-α for 12 hrs. Here we 
would like to emphasize that, we used the above experimental setup to study the function 
of BRD4 in almost all treatments to HUVECs, unless otherwise stated. We firstly checked 
the cell viability of both sets of treatments to confirm that treatments do not have significant 
cytotoxic effect. This analysis indicates that treatments alone or in combinations were not 







Figure 3.4 BRD4 inhibition using RVX208 and JQ1. A, bar graph shows percentage cell viability count in treatments 
with RVX208 after 12 hrs treatments. B, bar graph shows percentage cell viability count in treatments with JQ1 after 12 
hrs treatments. C, bar graph showing relative mRNA levels of inflammatory markers VCAM-I and IL6 after normalisation 
to house-keeping gene GAPDH, in HUVECs treated with DMSO, TNF-α-only, RVX208-only and RVX208+TNF-α D, bar 
graph showing relative mRNA levels of inflammatory markers VCAM-I and IL6 after normalisation to house-keeping gene 






biological replicates and asterisks indicate statistical significance of *** p< 0.001. E and F, immunofluorescence images 
for the effect of RVX (E) and JQ1 (F) on the cellular localization of NF-κB in response to indicated treatments. HUVECs 
were stained with anti-NF-κB antibody (red) and DAPI (blue). 
 
Then we performed the RNA expression analysis and found that pre-treatment with 
RVX208 could reduce the expression of inflammatory markers by 3-fold and 7-fold for 
VCAM-1 and IL6, respectively, as compared to TNF-α treatment (Fig. 3.4 C). Similarly, pre-
treatment with JQ1 could reduce the inflammatory markers by 8-fold and 10-fold for VCAM-
I and IL6, respectively, as compared to TNF-α treatment (Fig. 3.4 D). This analysis 
indicates that both JQ1 and RVX208 could efficiently inhibit the inflammatory response. 
Moreover, we also noted that the basal expression levels of inflammatory markers VCAM-
1 and IL6 were reduced by 3-fold and 5-fold, respectively, in JQ1-only treatment as 
compared to DMSO (Fig. 3.4 C and D). Similarly, RVX208-only treatment is also reducing 
the basal expression level of inflammatory markers VCAM-1 and IL6 by 1.4-fold and 2-fold, 
respectively, as compared to DMSO. 
To confirm that longer incubation (12 hrs) with RVX208 or JQ1 does not have any effect 
on translocation of NF-κB into the nucleus, we performed the immunostaining for NF-κB 
localization after above mentioned treatments. This analysis showed that NF-κB is present 
in the cytoplasm of control and RVX208/JQ1-only treated cells, whereas it translocated 
into the nucleus in TNF-α treated as well as in RVX208/JQ1+TNF-α treated cells (Fig. 3.4 
E and F). Hence, these results proved that RVX208/JQ1 pre-treatment followed by TNF-α 
does not affect the nuclear translocation of NF-κB.  
Collectively, our results show that BRD4 inhibition with either RVX208 or JQ1 suppresses 
the inflammatory response in HUVECs. In this context, it is interesting to note that BRD4 
has two different isoforms namely, BRD4-long (BRD4-L) and BRD4-short (BRD4-S), which 
have differential roles in different diseases. In particular, the differential expression of 
BRD4 isoforms is associated with metastasis in colon and breast cancers, in which BRD4-
S isoform enhances the breast cancer metastasis whereas BRD4-L isoform inhibits 
metastasis (Alsarraj et al., 2013; Hu et al., 2015). We were interested to determine the 
expression of BRD4 isoforms in normal as well as in inflammatory states of ECs. Hence, 
we wanted to study the expression pattern of BRD4 isoforms not only in HUVECs in normal 
and inflammatory conditions but also during BRD4 inhibition studies and in CVDs models 




3.3 Elucidating the role of BRD4 isoforms in endothelial dysfunction 
and in disease models 
3.3.1 BRD4 isoform analysis in HUVECs 
In order to determine the expression pattern of BRD4 isoforms in tissues of different 
diseases, we first decided to check the total mRNA levels of BRD4 (BRD4-Total) in our 
established system. HUVECs were treated as in above described experiments. We found 
that there is higher expression of BRD4-Total by 1.3-fold to 1.4-fold after 12 hrs of TNF-α 
treatment as compared control (DMSO). Treatments with either of RVX208 or JQ1 only, 
reveals a reduced expression of BRD4-Total by 1.6-fold and 1.8-fold in RVX208 and JQ1, 
respectively (Fig. 3.5A and B). These results led us to analyse the isoform specific 
expression of BRD4 during Inflammatory response or during treatment with RVX28 or JQ1. 
In order to analyse relative mRNA expression of BRD4-L and BRD4-S isoforms, Isoform 
specific primers were designed. BRD4-L and BRD4-S expression was first normalised to 
housekeeping gene GAPDH and then to BRD4-Total expression. Our data shows that 
there is no significant difference in expression levels of BRD4-L and BRD4-S isoforms 
during inflammatory response (TNF-α treatment) (Fig. 3.5 C and D). However, we 
observed that treatment with RVX208-only or JQ1-only results in reduced expression of 
BRD4-L by 1.75-fold and 2.5-fold, respectively (Fig. 3.5 C-D). These results suggest, that 
the observed reduction in expression levels of BRD4-Total could be due to the reduced 








Figure 3.5. Expression analysis of BRD4 isoforms in HUVECs. A and B, Bar graph showing relative mRNA levels of 
BRD4-Total normalised to house-keeping gene, GAPDH in cells treated with DMSO-only (control), TNF-α-only, RVX208-
only, RVX208+TNF-α (A) or in cells treated with DMSO-only (control), TNF-α-only, JQ1-only , JQ1+TNF-α (B). C and D, 
Bar graph showing relative mRNA levels of BRD4-L and BRD4-S isoforms normalised first to house-keeping gene 
GAPDH and then normalised to BRD4-total in in cells treated with DMSO-only (control), TNF-α-only, RVX208-only, 
RVX208+TNF-α ( C) or in cells treated with DMSO-only (control), TNF-α-only, JQ1-only , JQ1+TNF-α (D). Values are 
mean ± SEM of two biological replicates and asterisks indicate statistical significance of *** p< 0.001, ** p<0.01, and * 
p<0.05.  
 
We have then analysed the expression of BRD4 isoforms at protein level. We treated the 
cells as mentioned above and performed the Western blot analysis using anti-BRD4 
antibody. We found that the cells treated with TNF-α-only have higher expression of BRD4-






or JQ1 followed by TNF-α treatment show higher expression of BRD4-S isoforms by 1.6-
fold and 1.4-fold, respectively (Fig. 3.6A-B).  
 
 
Figure 3.6. Expression analysis of BRD4 protein in HUVECs A-B. Western blot image (left Panels) and the 
corresponding relative quantification bar graph (right panels) showing the protein expression of BRD4-L and BRD4-S. 
Immunoblot was stripped and reprobed β-actin antibody. The β-actin (~42kDa) was used as a loading control. The band 
intensities of BRD4-L and BRD4-S were normalized to β-actin. The number symbol (#) indicates a band of~100kDa with 
an un-known identity detected using BRD4 antibody. Values are mean ± SEM of two biological replicates and asterisks 
indicate statistical significance of *** p< 0.001, ** p<0.01 and * p<0.05. 
 
Collectively, our results indicate that mRNA levels, but not protein levels, of BRD4-L are 
reduced when treated with either RVX208- or JQ1-only. In contrast to the RNA data, protein 
levels of BRD4-S isoform were slightly increased during inflammatory response and it was 
still high when there is pre-treatment with BRD4 inhibitors, RVX208 or JQ1. Hence, it would 
be interesting to analyse whether BRD4 isoforms show any specific expression pattern in 
long-term disease conditions/models as opposed to short-term in vitro studies. Towards 
this end, we wanted to study the BRD4 isoform expression in CVDs like aging mice hearts 





3.3.2 BRD4 isoforms expression analysis in CVDs models 
It is known that aging increases the risk of CVDs and about 90% of heart failures are 
associated with patient older than 70 years (Strait and Lakatta, 2012). Patients older than 
65 years have high risk of inflammatory diseases. Expression analyses of inflammatory 
markers like IL6 and TNF-α are elevated with aging (Kritchevsky et al., 2005). Results 
showing a high expression levels of BRD4-S isoform during inflammation in HUVECs, led 
us to analyse expression pattern of BRD4 isoforms in hearts old aging mice. We collected 
hearts from wild-type C57BL/6 mice at age of 1-, 3-, 6-, 8-, 12-, 15-, and 18-months. Hearts 
were pulverized in liquid nitrogen and used for RNA isolation. We analysed mRNA 
expression levels of Brd4-Total (Fig. 3.7A) and Brd4 isoforms (Fig. 3.7B). We found that 
there is no significant difference of expression of BRD4-Total in hearts of 1- to 18-months-
old mice (Fig. 3.7A). Analysis of isoform-specific expression revealed no significant 
difference in mRNA expression of both isoforms, except for 6-month-old mice heart, which 
showed significantly higher Brd4-S expression (Fig. 3.7B). At the protein level, BRD4-L 
expression was similar in all samples, but significantly higher in hearts of 18-month-old 
mice (Fig. 3.7C). However, BRD4-S expression is only detectable till 8-months old mice 
heart (Fig. 3.7C). 
It is known that there is an increase in expression of inflammatory genes in pressure 
overloaded hearts (Chen et al., 2015; Souders et al., 2012). In this context, it would be 
interesting to analyse whether BRD4 has any expression changes in pressure overloaded 
TAC and its experimental control, SHAM, mice hearts. To this end, total proteins were 
isolated from TAC and SHAM mice hearts 20 weeks after surgery and subsequently 
subjected to western blotting analysis. We found that there was no significant expression 





Figure 3.7. Expression of BRD4 isoforms in mice hearts. Bar graph showing relative mRNA level of Brd4-Total 
normalised to house-keeping gene, Gapdh (A) and, Brd4-L and Brd4-S isoforms normalised first to house-keeping gene 
Gapdh and then normalised to Brd4 total (B) in 1-, 3-, 6-, 8-, 12-, 15-, and 18- months old mice hearts. C and D, Western 
blot image (left Panels) and the corresponding relative quantification bar graph (right Panels) showing the protein 
expression of BRD4-L and BRD4-S in 1- to 18-months old mice (C) and in WT-SHAM and WT-TAC mice hearts (D). 
Immunoblotting for β-actin was used as a loading control. The band intensities of BRD4-L and BRD4-S were normalized 
to β-actin. Values are mean ± SEM of three (two in B) biological replicates and asterisks indicate statistical significance 
of ** p<0.01 and * p<0.05. 
 
In mouse models of CVDs, we found indecisive results that BRD4-L isoform expression is 





after 8-months of age. Likewise, there was no significant difference of BRD4-L and BRD4-
S isoforms in cardiac hypertrophic mice hearts (TAC) as compared to SHAM mice. This 
data may indicate that BRD4 isoforms expression do not vary during cardiac remodelling 
of hearts in hypertrophy. After expression analysis of BRD4 isoforms, we further 
investigated the role of BRD4 in monolayer integrity of ECs. 
 
3.4 Identifying the role of BRD4 and Midkine in monolayer integrity 
of endothelium 
3.4.1 Effect of inflammatory phenotype on HUVECs monolayer integrity 
It has been reported that TNF-α treatment results in increased permeability and monolayer 
disruption in vascular ECs (Friedl et al., 2002; Royall et al., 1989). Likewise, retinal ECs 
also lose monolayer integrity because of disruption of tight junctions via activation of NF-
κB signalling (Aveleira et al., 2010). In order to analyse the effect of TNF-α treatment on 
HUVECs monolayer integrity, we used Trans-Endothelial/Epithelial Electrical Resistance 
(TEER) measurement test and the change in electrical resistance as an indicator of 
monolayer integrity. To perform TEER measurements, HUVECs were grown on 0.4 μM 
pore size transwell membranes for 3-5 days until cells formed the monolayer and showed 
a reference value of ~80 Ω.cm2 (Callahan et al., 2004; Kazakoff et al., 1995; Man et al., 
2008; Srinivasan et al., 2015). Afterwards, HUVEC monolayers were treated with either 
with DMSO or TNF-α for 12 hrs and measured for electrical resistance at different time 
intervals (0-, 3-, 6-, and 12 hrs). There was a significantly reduced electrical resistance 
across TNF-α treated monolayer compared to control (DMSO) treated monolayer, 
indicating increased permeability and loss of monolayer integrity in TNF-α treated cells 














Figure 3.8. Disruption of monolayer integrity in HUVECs : HUVECs were grown on 0.45 μM transwell membrane for 
5 days to establish the monolayer. Line graph shows Transepithelial/endothelial electrical resistance (TEER) measured 
in HUVECs monolayer treated with DMSO and TNF-α for 12 hrs. Values are mean ± SEM of three biological replicates 
and asterisks indicate statistical significance of *** p< 0.001.  
 
Next, we were interested to study whether BRD4 inhibition could preserve the monolayer 
integrity in TNF-α treated monolayer as BRD4 inhibition is shown to reduce the 
inflammatory response, which is known to be associated with monolayer disruption.  
3.4.2 BRD4 inhibition protects HUVECs monolayer integrity 
To analyse the effect of BRD4 inhibition on monolayer integrity, HUVECs monolayers were 
treated with DMSO-only-, TNF-α-only-, RVX208-only-, and RVX208 followed by TNF-α. 
Similarly, the second set of monolayers was treated with JQ1 instead of RVX208. After the 
indicated treatments, the monolayers were subjected to TEER measurement at different 
time intervals. As expected, TNF-α treated cells showed significantly reduced electrical 
resistance as compared to control (DMSO). Surprisingly, when HUVEC monolayers were 





resistance across the monolayer (Fig. 3.9A-B). Hence, these results indicate that BRD4 
inhibition is also protecting the HUVECs monolayer integrity from inflammatory response. 
 
Figure 3.9. BRD4 inhibition, protects monolayer integrity in HUVECs. HUVECs were grown on 0.45 μM transwell 
membrane for 5 days to establish the monolayer Line graphs showing Transepithelial/endothelial electrical resistance 
(TEER) measured in HUVEC monolayers treated with DMSO, TNF-α-only, RVX208-only and RVX208+TNF-α (A), and 
with DMSO, TNF-α-only, JQ1-only and JQ1+TNF-α (B). Values are mean ± SEM of three biological replicates and 
asterisks indicate statistical significance of *** p< 0.001.  
 
Next, we wanted to investigate the mechanism through which BRD4 inhibition is preserving 
the monolayer integrity. Here we would like to highlight that our group has previously shown 
that increased monolayer permeability is associated with Midkine/PI3K pathway in human 
epithelial colorectal adenocarcinoma cells (Caco-2 cells) (Khan et al., 2017). To evaluate 
whether the same mechanism/pathway is responsible for the loss of monolayer integrity in 
HUVECs, we decided first to analyse mRNA expression of these genes during 





with TNF-α for 2 and 12 hrs. Induced mRNA expression levels of pro-inflammatory gene 
(SELE) in TNF-α treated monolayers confirmed the inflammatory phenotype as compared 
to non-treated control monolayers (Fig. 3.10A). Then the expression of p38MAP Kinase 
(p38MAPK) and MIDKINE was measured (Fig. 3.10B). As our data indicated higher 
expression of p38MAPK and MIDKINE in TNF-α treated monolayers, we decided to 
explore the role of MIDKINE, which is an upstream regulator of p38MAPK, in conjunction 
with BRD4 in our experimental setup. 
Figure 3.10. Induction of MIDKINE and p38MAPK expression in HUVECs: A, Bar graph showing mRNA levels of 
SELE after normalisation to house-keeping gene GAPDH in Control (non-treated) and in TNF-α treated (2hrs and 12hrs) 
monolayers. B, Bar graph showing mRNA levels of P38MAPK and MIDKINE after normalisation to house-keeping gene 
GAPDH in non-treated control and in TNF-α treated (2 hrs and 12 hrs) monolayers. Values are mean ± SEM of two 
biological replicates and asterisks indicate statistical significance of *** p< 0.001. 
 
3.4.3 TNF-α induces the expression of Midkine 
Endothelium releases a basal level of Midkine, a cytokine, in normal healthy state, where 
it is known to play a role in angiogenesis, apoptosis, growth and repair of damaged tissues 
(Kadomatsu et al., 2014; Salaru et al., 2016). Increased expression of Midkine has been 
reported in inflammatory kidney disease and atherosclerosis (Kadomatsu et al., 2014; 
Salaru et al., 2013; Salaru et al., 2016). Hence, we decided to check Midkine expression 
in HUVEC monolayers treated with 20 ng/ml TNF-α for 6-, 12-, 24-, 48-, and 72- hrs. The 
mRNA expression of MIDKINE was significantly high after 6 hrs of TNF-α treatment and it 
steadily increased until 72hrs of treatment (Fig. 3.11A).  
Western blot analysis on total protein extracts of above treatments failed to detect the band 
corresponding to MIDKINE (Fig. 3.11B). Midkine is released from cell and acts as a 





monolayer for MIDKINE protein. This analysis indicated that Midkine protein secretion was 
significantly high in HUVECs treated with TNF-α for 48 hrs-72 hrs (Fig. 3.11C).  
 
Figure 3.11. Midkine expression in HUVEC monolayer during TNF-α treatment: A, Bar graph showing relative mRNA 
levels of MIDKINE after normalization to house-keeping gene, GAPDH, in control and after different times of TNF-α 
treatments (6-, 12-, 24-, 48- and 72-hrs). B, Western Blot showing MIDKINE and β-actin expression in control and TNF-
α treatments (6-, 12-, 24-, 48- and 72-hrs). C, Western blot image (upper panel) and the corresponding relative 
quantification bar graph showing the protein expression of MIDKINE secretion (lower panel) in control and TNF-α 
treatments (6-, 12-, 24-, 36-, 48-, and 72hrs). Ponceau staining of the Western blot membrane showing a band of 
unknown identity at ~55 kDa as a loading control. Values are mean ± SEM of three biological replicates and asterisks 
indicate statistical significance of *** p< 0.001 and ** p<0.01. 
 
This finding together with our previous observation that Midkine disrupts tight junctions and 






Midkine could be the reason for disruption of tight junctions in HUVEC monolayers, as well. 
Hence, it would be interesting to analyse the effect of BRD4 inhibition on MIDKINE 
expression and the monolayer integrity properties of HUVECs. 
3.4.4 BRD4 inhibition reduces the expression of Midkine 
To study the effect of BRD4 inhibition on Midkine expression, HUVEC monolayers were 
pre-treated either with or without RVX208 or JQ1 for 12 hrs before treating them with TNF-
α for 6-, 12-, 24-, 36-, 48- and 72-hrs. RNA expression analysis showed significantly 
reduced expression of MIDKINE in monolayers pre-treated with Inhibitor (RVX208 or JQ1) 










Figure 3.12. Midkine inhibition in HUVECs with BRD4 inhibitors A, Bar graph showing relative mRNA levels of 
MIDKINE after normalization to house-keeping gene GAPDH, in control and TNF-α treatments (6-, 12-, 24-, 48- and 72-
hrs), RVX 208 treatment and pre-treatment with RVX208 followed by TNF-α (6-, 12-, 24-, 36-, 48-, and 72-hrs). B, Bar 
graph showing relative mRNA levels of MIDKINE after normalization to house-keeping gene GAPDH, in control and TNF-
α treatments (6-, 12-, 24-, 48- and 72-hrs), JQ1 treatment and pre-treatment with JQ1 followed by TNF-α (6-, 12-, 24-, 
36-, 48-, and 72-hrs) .C, Western blot image showing the protein expression of MIDKINE secretion (upper panel) in 
control, TNF-α treatments (36-, 48-, and 72-hrs), Pre-treatment with RVX208 or JQ1 followed by 48- and 72-hrs of TNF-
α treatment. Ponceau staining (lower panel) of the Western blot membrane showing a band of unknown identity at 
~55kDa as a loading control. Values are mean ± SEM of three biological replicates and asterisks indicate statistical 
significance of *** p< 0.001, ** p<0.01 and * p<0.05 . 
 
Next, we checked the supernatants of HUVEC monolayer cultures for secreted Midkine 
protein. Monolayers were treated either with RVX208 or JQ1 or were treated with RVX208 
or JQ1 followed by TNF-α treatment for 48 and 72 hrs. Protein secretion of MIDKINE was 
significantly reduced in cells pre-treated with BRD4 inhibitor followed by TNF-α treatment, 






expression and secretion was significantly high in response to TNF-α treatment. However, 
BRD4 inhibition via JQ1 or RVX208, decreases the expression of Midkine during TNF-α 
treatment. These results indicate that MIDKINE might be another target of BRD4 during 
inflammatory response in HUVECs and inhibition of BRD4 results in decreased expression 
of MIDKINE. 
Collectively, we can conclude that BRD4 inhibition not only alleviates the inflammatory 
response in HUVECs but also preserves endothelial monolayer integrity via reducing the 
Midkine expression. 
 
3.5 Expression of PTP1B increases in ECs during inflammation 
Protein Tyrosine Phosphatase 1B (PTP1B) is another protein which has higher expression 
during inflammation (Zabolotny et al., 2008). And enhanced expression of PTP1B in ECs 
is associated with reduced angiogenesis and reduced expression of endothelial specific 
nitric oxide synthase (eNOS) (Besnier et al., 2014; Lanahan et al., 2014). Then we want to 
analyse whether PTP1B is highly expressed also in our in-vitro inflammatory model. For 
this reason, we treated the HUVECs with TNF-α for 2 hrs and analysed the mRNA level of 
PTP1B. We found no significant expression difference of PTP1B in control and TNF-α 
treated cells. So, then we treated HUVECs with TNF-α for various time points (6-,12-, and 
24-hrs) and found significant up-regulation of PTP1B mRNA levels already by 6 hrs of 
treatment, which is further increased by 24 hrs (Fig. 3.13 A).  
Next, we performed the western blot analysis using anti-PTP1B antibody and found 
significantly increase in expression of PTP1B protein only after 24 hrs of TNF-α treatment 
(Fig. 3.13B). These results highlight that PTP1B is up-regulated during inflammatory 






Figure 3.13. Induction of PTP1B expression in HUVECs. A, Bar graph showing relative mRNA levels of PTP1B after 
normalization to house-keeping gene GAPDH in control, and TNF-α treatments (6-, 12- and 24-hrs). B, Western blot 
image (upper panel) and the corresponding relative quantification bar graph (lower panel) showing the protein expression 
of PTP1B in control and TNF-α treated (6-, 12- and 24-hrs). Immunoblotting for β-actin was used as a loading control. 
The band intensities of Midkine were normalized to β-actin. Values are mean ± SEM of two biological replicates and 
asterisks indicate statistical significance of *** p< 0.001 and ** p<0.01 
 
In this context it is interesting to note that deletion or pharmacological inhibition of PTP1B 
in mice protects them against diabetes and obesity (Ali et al., 2009) and hypertension 
(Bruder-Nascimento et al., 2015). It has been reported that PTP1B deletion reduces 
endothelial dysfunction by improving Nitric oxide (NO) production, improves cardiac 
dysfunction and cardiac inflammation (Coquerel et al., 2014). Importantly endothelial 
specific PTP1B deletion in mice (Endo.Ptp1b.KO) protected them against induced cardiac 
hypertrophy and fibrosis in TAC model (Gogiraju et al., 2016). This finding prompted us to 
analyse the global proteome of heart tissues derived from Endo.Ptp1b.KO to identify 
possible targets/pathways of Ptp1b, which are responsible for the observed rescue.  
 
3.6 Global Proteome analysis  
In order to achieve a comparative global proteome profiling between Endo.Ptp1b.KO and 
Wild type (Endo.Ptp1b.WT) mouse hearts, the strategy illustrated in figure 3.11 was 
employed. Briefly, mice with loxP flanked Ptp1b allele (Ptp1bfl/fl) were bred either with Wild 
type mice or with transgenic mice expressing a fusion protein of Cre recombinase-estrogen 





(Tie2.ERT2.Cre). The off-spring were then fed with Tamoxifen diet to induce Cre 
recombinase activity. Afterwards, 10-12 weeks-old females WT and KO females were 
subjected to TAC or SHAM surgery (Fig. 3.14). In TAC group, a band is placed around the 
aorta of mice to induce pressure on heart, while SHAM mice (an experimental control) 
group also underwent surgery although aortic arch was exposed but no band was placed 
around the aorta. This strategy gave rise to four groups of animals namely: 1. Wild-type 
SHAM (WT-SHAM), 2. Wild-type TAC (WT-TAC), 3. Endothelial-specific Ptp1b knockout 
SHAM (KO-SHAM), and 4, Endothelial-specific Ptp1b knockout TAC (KO-TAC). After 20 
weeks of TAC/SHAM surgery, five independent animals were taken from each group as 
biological replicates and whole heart tissue lysates were prepared in the presence of 
protease and phosphatase inhibitors (Fig. 3.14). Afterwards, 50 μg of proteins were tryptic 
digested and the resulting peptides were subjected to liquid chromatography-tandem mass 














Fig. 3.14. Schematic illustration of strategy for global proteome analysis. Ptp1bfl/fl mice were either crossed with 
Wild type or with transgenic Tie2.ERT2.Cre mice and the resulting off-spring (6-week-old) were fed with tamoxifen diet 
for other 6-weeks to induce Cre-recombinase activity and to obtain Endo.Ptp1b.WT or Endo.Ptp1b.KO mice, respectively. 
Both animal groups underwent the TAC or SHAM surgery and gave rise to four groups: WT-TAC, WT-SHAM, KO-SHAM 












analysis. Then Perseus based statistical analysis was employed to identify the significant proteins. STRING pathway 
analysis was performed to identify the sub-cellular localization of proteins for better understanding of their functions.  
 
Following the data acquisition, we performed quantitative proteome analysis by using 
Sequential Window Acquisition of all THeoretical fragment ion spectra (SWATH) in data 
independent acquisition (DIA) mode. Overall, we identified a total of 899 common proteins 
in all four groups and quantified 697 proteins with 1% False Discovery Rate (FDR). Then, 
we analysed all 697 proteins by using directed Principal Component Analysis (PCA) to get 
an overview of variability in our data. We observed four clusters representing four analysed 
groups with all the biological and technical replicates falling into their respective clusters 
(Fig. 3.15). WT-SHAM and KO-SHAM were more closely clustered to each other, indicating 
less variability among the SHAM groups. Interestingly, TAC groups (KO-TAC and WT TAC) 
represented two distinct clusters, highlighting that the rescue of cardiac overload has a 














Fig. 3.15. Global proteome analysis: PCA analysis based on whole-proteome levels, which confirmed the presence of 
the 4 different groups. Different groups were assigned to proteins on basis of differential expression Blue colour 
represents WT-SHAM group, Orange colour represents WT-TAC, Green colour represents KO-SHAM and Red colour 







3.6.1 Statistical Analysis using Perseus Software 
After-knowing that KO-TAC and WT-TAC mice had a different proteome compared to 
SHAM groups, we decided to perform statistical analysis using Perseus software to identify 
proteins that have significant expression differences. For this reason, we compared the 
following groups: 
Group A: WT-SHAM and KO-SHAM Group B: WT-SHAM and WT-TAC 
Group C: KO-SHAM and KO-TAC Group D: WT-TAC and KO-TAC 
Next, we calculated p-values for all four groups followed by fold change calculation. We 
considered proteins with p values < 0.05 and fold change cut-off value of 1.5 as significantly 
different and used them for further analysis. In Group A, we found 8 proteins to be up-
regulated, while 58 proteins to be down-regulated in KO-SHAM as compared to WT-SHAM 
(Table 3.1, 3.2, and Fig. 3.16) In Group B, 60 and 70 proteins were up- and down-
regulated, respectively, (Table 3.3, 3.4, and Fig. 3.16) in WT-TAC as compared to WT-
SHAM. In Group C, 150 proteins were up-regulated while 53 proteins were down-regulated 
in KO-TAC as compared to KO-SHAM, (Tables 3.5, 3.6, and Fig. 3.16). In Group D: 43 
proteins were up-regulated while 36 were down-regulated in KO-TAC as WT-TAC (Table 













Figure 3.16. Statistical summary of Global proteome analysis: Bar graph indicating number of up-regulated (red) 
and down-regulated (green) proteins in all four groups. The number of proteins in bar graph denote those that reached 
statistical significance using Welch’s T-test. 
 
Next, we converted the p-values into -log10 (p-values) and fold change was converted in 
log2 (log2 FC) and volcano plots were plotted using -log10 of p-values against log2 of fold 
change (Fig. 3.17A-D).  
Table 3.1  
Group A: Up-regulated Proteins in KO-SHAM vs WT-SHAM 
Uniprot Accession Protein Fold Change 
NDUA3_MOUSE NADH dehydrogenase 1 alpha subcomplex subunit 3 9.261803 
CXA1_MOUSE Gap junction alpha-1 protein 2.333574 
2AAA_MOUSE 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform 2.271057 
Q7JCZ3_MOUSE Cytochrome b 2.19333 
A0A0G2JH00_MOUSE Protein Igkv4-61 2.1896 





NDUA7_MOUSE NADH dehydrogenase 1 alpha subcomplex subunit 7 1.679112 
ACADS_MOUSE Short-chain specific acyl-CoA dehydrogenase, mitochondrial 1.588391 
 
Table 3.2  
Group A: Down-regulated Proteins in KO-SHAM vs WT-SHAM 
Uniprot Accession Protein Fold Change 
SPA3K_MOUSE Serine protease inhibitor A3K 5.724768 
Q3UER8_MOUSE Fibrinogen gamma chain 5.59055 
Q58E64_MOUSE Elongation factor 1-alpha 4.41397 
Q9CPX4_MOUSE Ferritin 4.184854 
Q52L87_MOUSE Tubulin alpha-1C chain 3.284082 
Q58E35_MOUSE 60S acidic ribosomal protein P1 3.249365 
E9Q5L2_MOUSE Inter alpha-trypsin inhibitor, heavy chain 4 3.172823 
Q149V4_MOUSE Histone H2A 2.851051 
AN32A_MOUSE Acidic leucine-rich nuclear phosphoprotein 32 family member A 2.690346 
D3Z576_MOUSE Filamin-C 2.55819 
FIBA_MOUSE Fibrinogen alpha chain 2.505103 
COF1_MOUSE Cofilin-1 2.465072 
Q5DQJ3_MOUSE 
Capping protein (Actin filament) muscle Z-line, alpha 2, isoform 
CRA_c 2.453384 
GNAS1_MOUSE 
Guanine nucleotide-binding protein G(s) subunit alpha isoforms 
XLas 2.332206 
A2AFJ1_MOUSE Histone-binding protein RBBP7 2.283441 
Q546K1_MOUSE Cytoglobin 2.23178 
RTN2_MOUSE Isoform 2 of Reticulon-2 2.221354 
PP1B_MOUSE 
Serine/threonine-protein phosphatase PP1-beta catalytic 
subunit 2.218909 
Q8BVQ9_MOUSE 26S protease regulatory subunit 7 2.188379 
SDCG8_MOUSE Serologically defined colon cancer antigen 8 homolog 2.157165 
RS9_MOUSE 40S ribosomal protein S9 2.09963 
A4FUS1_MOUSE 40S ribosomal protein S16 2.052678 
Q8C5G6_MOUSE Toll-interacting protein 2.029818 
Q5SUC3_MOUSE Calnexin 2.009529 
A0A075B6A0_MOUSE Ig mu chain C region  2.008865 
S4R1E5_MOUSE Glutathione peroxidase 2.006824 
ANXA3_MOUSE Annexin A3 1.970541 
TERA_MOUSE Transitional endoplasmic reticulum ATPase 1.908613 
Q499X4_MOUSE Synaptic vesicle membrane protein VAT-1 homolog 1.900839 
A3KGQ6_MOUSE Actin-related protein 2/3 complex subunit 5 1.857499 
Q3U4U6_MOUSE T-complex protein 1 subunit gamma 1.843001 
Q792A4_MOUSE Cox7ah 1.834669 




HSPB2_MOUSE Heat shock protein beta-2 1.825187 
Q564E8_MOUSE 60S ribosomal protein L4 1.806892 
Q545X8_MOUSE 40S ribosomal protein S4 1.798365 
DNJB4_MOUSE DNA homolog subfamily B member 4 1.794935 
TM14C_MOUSE Transmembrane protein 14C 1.781072 
Q3U367_MOUSE 4-trimethylaminobutyraldehyde dehydrogenase 1.756965 
GRPE1_MOUSE GrpE protein homolog 1, mitochondrial 1.749118 
A0A0H2UH17_MOUSE Ubiquitin associated protein 2-like, isoform CRA_b 1.72855 
Q5M8M8_MOUSE 60S ribosomal protein L29 1.704919 
G5E8J6_MOUSE Histidine rich calcium binding protein, isoform CRA_a 1.694952 
Q543B9_MOUSE Prolyl endopeptidase 1.684433 
CAND1_MOUSE Cullin-associated NEDD8-dissociated protein 1 1.678813 
Q5M9J2_MOUSE Histidine triad nucleotide binding protein 2 1.663793 
CD47_MOUSE Leukocyte surface antigen CD47 1.662129 
RL27A_MOUSE 60S ribosomal protein L27a 1.648814 
TNNC1_MOUSE Troponin C, slow skeletal and cardiac muscles 1.632444 
USMG5_MOUSE Up-regulated during skeletal muscle growth protein 5 1.60865 
Q3UCD9_MOUSE Cathepsin D 1.604517 
A0A0U1RQ27_MOUSE Methylmalonyl CoA epimerase, isoform CRA_c 1.573786 
B9EHN0_MOUSE Ubiquitin-activating enzyme E1, Chr X 1.573732 
Q3TJY2_MOUSE WD repeat domain 1 1.573184 
E9Q7N5_MOUSE Ribosome-releasing factor 2, mitochondrial 1.551304 
VTDB_MOUSE Vitamin D-binding protein 1.543408 
GDIR1_MOUSE Rho GDP-dissociation inhibitor 1 1.542594 
Q3UL22_MOUSE Chaperonin subunit 8 (Theta), isoform CRA_a 1.524054 
 
Table 3.3  
Group B: Up-regulated Proteins in WT-TAC vs WT-SHAM 
Uniprot Accession Protein Fold Change 
B2RXX9_MOUSE Myosin, heavy polypeptide 7, cardiac muscle, beta 22.46804 
A2AEX8_MOUSE Four and a half LIM domains 1, isoform CRA_b 4.475918 
Q8BFQ1_MOUSE Prosaposin 3.895401 
APOA2_MOUSE Apolipoprotein A-II 3.506413 
Q546K1_MOUSE Cytoglobin 3.194436 
NDUA3_MOUSE NADH dehydrogenase  1 alpha subcomplex subunit 3 2.944347 
D9J302_MOUSE ENH isoform 1e 2.922764 
TBB5_MOUSE Tubulin beta 2.672675 
NDUB2_MOUSE 
NADH dehydrogenase  1 beta subcomplex subunit 2, 
mitochondrial 2.565567 
Q4FJQ6_MOUSE 
Serine (Or cysteine) peptidase inhibitor, clade B, member 6a, 
isoform CRA_a 2.548441 
H7BX64_MOUSE Sarcolemmal membrane-associated protein 2.520141 




Q7JCZ3_MOUSE Cytochrome b 2.44693 
E9QLZ9_MOUSE Protein enabled homolog 2.410786 
G3X9L6_MOUSE MCG55033 2.36428 
A0A0A6YWR2_MOUSE Ig gamma-1 chain C region secreted form  2.243095 
UGPA_MOUSE UTP--glucose-1-phosphate uridylyltransferase 2.227797 
TXD17_MOUSE Thioredoxin domain-containing protein 17 2.17689 
F6ZFU0_MOUSE Elongation factor 1-delta  2.131331 
HEMO_MOUSE Hemopexin 2.129784 
HDHD2_MOUSE 
Haloacid dehalogenase-like hydrolase domain-containing protein 
2 2.074073 
ANXA7_MOUSE Annexin A7 2.073107 
Q6YJU1_MOUSE Fetuin-B 1.985978 
STIP1_MOUSE Stress-induced-phosphoprotein 1 1.984306 
CAH1_MOUSE Carbonic anhydrase 1 1.964014 
S4R1E5_MOUSE Glutathione peroxidase 1.961202 
TOM70_MOUSE Mitochondrial import receptor subunit TOM70 1.925854 
OBSCN_MOUSE Obscurin 1.912945 
PSA6_MOUSE Proteasome subunit alpha type-6 1.904566 
F6TCV0_MOUSE Serine protease HTRA2, mitochondrial  1.896703 
Q3T9Z2_MOUSE Glyoxylate reductase/hydroxypyruvate reductase 1.882532 
SLIRP_MOUSE SRA stem-loop-interacting RNA-binding protein, mitochondrial 1.877301 
GCAM_MOUSE Ig gamma-2A chain C region, membrane-bound form 1.873636 
TIM13_MOUSE Mitochondrial import inner membrane translocase subunit Tim13 1.869761 
Q543M7_MOUSE Importin subunit alpha 1.850016 
Q545C7_MOUSE Cysteine and glycine-rich protein 3 1.848998 
Q542Y0_MOUSE NAD(P)H dehydrogenase [quinone] 1 1.803744 
ENOB_MOUSE Beta-enolase 1.801966 
Z4YK42_MOUSE NAD kinase 2, mitochondrial 1.786285 
MIRO1_MOUSE Isoform 4 of Mitochondrial Rho GTPase 1 1.779831 
F6WYM0_MOUSE Septin-2  1.776692 
A0A0G2JH00_MOUSE Protein Igkv4-61  1.770807 
HSPB6_MOUSE Heat shock protein beta-6 1.759373 
MYL1_MOUSE Myosin light chain 1/3, skeletal muscle isoform 1.757874 
E9Q616_MOUSE Protein Ahnak 1.751377 
OLA1_MOUSE Obg-like ATPase 1 1.74836 
PYRD_MOUSE Dihydroorotate dehydrogenase (quinone), mitochondrial 1.735936 
GPD1L_MOUSE Isoform 2 of Glycerol-3-phosphate dehydrogenase 1-like protein 1.702011 
A2AIW9_MOUSE Mitochondrial-processing peptidase subunit alpha 1.684361 
A0A0G2JFH2_MOUSE Microtubule-associated protein  1.681806 
2AAA_MOUSE 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform 1.677898 
F2Z456_MOUSE NADH-cytochrome b5 reductase 1.657675 
PDC6I_MOUSE Programmed cell death 6-interacting protein 1.656956 
BDH_MOUSE D-beta-hydroxybutyrate dehydrogenase, mitochondrial 1.64578 




Q3TJY2_MOUSE WD repeat domain 1 1.600595 
DNJA2_MOUSE DnaJ homolog subfamily A member 2 1.588696 
B7ZCI2_MOUSE Nebulette 1.584902 
F8WIA1_MOUSE CAP-Gly domain-containing linker protein 1 1.575521 
E9Q3X0_MOUSE Major vault protein 1.567592 
LEG1_MOUSE Galectin-1 1.566273 
 
Table 3.4 
Group B: Down-regulated Proteins in WT-TAC vs WT-SHAM 
Uniprot Accession Protein Fold Change 
Q58E35_MOUSE 60S acidic ribosomal protein P1 7.177066 
Q9CPX4_MOUSE Ferritin 4.297613 
A1BG_MOUSE Alpha-1B-glycoprotein 4.065593 
Q8BTU6_MOUSE Eukaryotic initiation factor 4A-II 3.96271 
G5E8J6_MOUSE Histidine rich calcium binding protein, isoform CRA_a 3.869917 
FRIH_MOUSE Ferritin heavy chain 3.731264 
Q52L87_MOUSE Tubulin alpha-1C chain 3.45146 
ABCB8_MOUSE ATP-binding cassette sub-family B member 8, mitochondrial 3.345933 
Q3U367_MOUSE 4-trimethylaminobutyraldehyde dehydrogenase 3.233596 
KV3A4_MOUSE Ig kappa chain V-III region 50S10.1 2.888454 
SPA3K_MOUSE Serine protease inhibitor A3K 2.837102 
E9QMK9_MOUSE Protein 9030617O03Rik 2.813919 
THIM_MOUSE 3-ketoacyl-CoA thiolase, mitochondrial 2.793903 
B2RUK5_MOUSE Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial 2.621667 
CES1D_MOUSE Carboxylesterase 1D 2.557144 
A0A075B6A0_MOUSE Ig mu chain C region  2.486141 
RLA2_MOUSE 60S acidic ribosomal protein P2 2.451661 
Q5DQJ3_MOUSE 
Capping protein (Actin filament) muscle Z-line, alpha 2, isoform 
CRA_c 2.363354 
ECI1_MOUSE Enoyl-CoA delta isomerase 1, mitochondrial 2.353803 
NDUB4_MOUSE NADH dehydrogenase  1 beta subcomplex subunit 4 2.310692 
Q4FK74_MOUSE ATP synthase subunit delta, mitochondrial 2.270961 
Q0PD66_MOUSE RAB1B, member RAS oncogene family, isoform CRA_c 2.267102 
CXA1_MOUSE Gap junction alpha-1 protein 2.243188 
NIT2_MOUSE Omega-amidase NIT2 2.156661 
Q32P04_MOUSE Keratin 5 2.149984 
A0A0U1RPI1_MOUSE Phospholemman 2.125259 
Q7JCX7_MOUSE Cytochrome c oxidase subunit 3 2.097943 
G3X9J1_MOUSE Sodium/calcium exchanger 1 2.091153 
LDHB_MOUSE L-lactate dehydrogenase B chain 2.079872 
NDUB1_MOUSE NADH dehydrogenase  1 beta subcomplex subunit 1 2.04942 
COQ3_MOUSE Ubiquinone biosynthesis O-methyltransferase, mitochondrial 2.02944 




LAMA2_MOUSE Laminin subunit alpha-2 1.985002 
ADCK3_MOUSE Atypical kinase ADCK3, mitochondrial 1.960187 
HHATL_MOUSE Protein-cysteine N-palmitoyltransferase HHAT-like protein 1.927543 
A0A0A0MQ68_MOUSE Glutaryl-CoA dehydrogenase, mitochondrial 1.866263 
ACOT2_MOUSE Acyl-coenzyme A thioesterase 2, mitochondrial 1.865219 
TERA_MOUSE Transitional endoplasmic reticulum ATPase 1.861359 
TACO1_MOUSE Translational activator of cytochrome c oxidase 1 1.841498 
TRAP1_MOUSE Heat shock protein 75 kDa, mitochondrial 1.810444 
CAD13_MOUSE Cadherin-13 1.796888 
ECHD2_MOUSE Enoyl-CoA hydratase domain-containing protein 2, mitochondrial 1.775955 
HCDH_MOUSE Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial 1.769064 
PYGM_MOUSE Glycogen phosphorylase, muscle form 1.768924 
RM12_MOUSE 39S ribosomal protein L12, mitochondrial 1.757314 
IVD_MOUSE Isovaleryl-CoA dehydrogenase, mitochondrial 1.751905 
RL14_MOUSE 60S ribosomal protein L14 1.72281 
CD47_MOUSE Leukocyte surface antigen CD47 1.714945 
ECHB_MOUSE Trifunctional enzyme subunit beta, mitochondrial 1.709272 
CAV1_MOUSE Caveolin-1 1.707292 
Q80ZZ0_MOUSE EH domain-containing protein 1 1.685678 
USMG5_MOUSE Up-regulated during skeletal muscle growth protein 5 1.670951 
B2RS41_MOUSE Aldhehyde dehydrogenase family 5, subfamily A1 1.670343 
TMM65_MOUSE Transmembrane protein 65 1.664084 
CACP_MOUSE Carnitine O-acetyltransferase 1.659263 
NNRE_MOUSE NAD(P)H-hydrate epimerase 1.647341 
GSTK1_MOUSE Glutathione S-transferase kappa 1 1.64678 
Q14AZ9_MOUSE Zinc binding alcohol dehydrogenase, domain containing 2 1.633292 
CPT2_MOUSE Carnitine O-palmitoyltransferase 2, mitochondrial 1.616862 
MTFP1_MOUSE Mitochondrial fission process protein 1 1.613282 
ACADM_MOUSE Medium-chain specific acyl-CoA dehydrogenase, mitochondrial 1.598459 
F8WIT2_MOUSE Annexin 1.589367 
TNNC1_MOUSE Troponin C, slow skeletal and cardiac muscles 1.584537 
ECHA_MOUSE Trifunctional enzyme subunit alpha, mitochondrial 1.576044 
Q497X4_MOUSE Cathepsin R 1.570785 
Q569W4_MOUSE Acetyl-coenzyme A synthetase 1.554089 
B1AR28_MOUSE Very long-chain-specific acyl-CoA dehydrogenase, mitochondrial 1.537874 
E9Q800_MOUSE MICOS complex subunit MIC60 1.527675 
PDK2_MOUSE 




Group C: Up-regulated Proteins in KO-TAC vs KO-SHAM 




Q546K1_MOUSE Cytoglobin 8.179658 
B2RXX9_MOUSE Myosin, heavy polypeptide 7, cardiac muscle, beta 7.751299 
Q3UER8_MOUSE Fibrinogen gamma chain 6.92076 
NNTM_MOUSE NAD(P) transhydrogenase, mitochondrial 6.404869 
Q8C5G6_MOUSE Toll-interacting protein 4.803583 
S4R1E5_MOUSE Glutathione peroxidase 4.76199 
RTN2_MOUSE Isoform 2 of Reticulon-2 4.211308 
GNAS1_MOUSE 
Guanine nucleotide-binding protein G(s) subunit alpha isoforms 
XLas 4.191142 
Q58E64_MOUSE Elongation factor 1-alpha 4.157227 
Q792A4_MOUSE Cox7ah 4.135588 
F6TCV0_MOUSE Serine protease HTRA2, mitochondrial  4.06327 
Q3UP42_MOUSE Protein S100-A9 3.921346 
Q542X7_MOUSE Chaperonin subunit 2 (Beta), isoform CRA_a 3.866951 
Q8BH80_MOUSE Vesicle-associated membrane protein, associated protein B and C 3.813203 
A3KGQ6_MOUSE Actin-related protein 2/3 complex subunit 5 3.709066 
TM14C_MOUSE Transmembrane protein 14C 3.630261 
Q542I9_MOUSE 26S protease regulatory subunit 4 3.286168 
PDIA1_MOUSE Protein disulfide-isomerase 3.276221 
SPA3K_MOUSE Serine protease inhibitor A3K 3.256386 
Q3UW66_MOUSE Sulfurtransferase 3.194263 
A2AFJ1_MOUSE Histone-binding protein RBBP7 3.132479 
A2AEX8_MOUSE Four and a half LIM domains 1, isoform CRA_b 3.085688 
E9Q5L2_MOUSE Inter alpha-trypsin inhibitor, heavy chain 4 3.072361 
E9Q7N5_MOUSE Ribosome-releasing factor 2, mitochondrial 2.989694 
D3Z576_MOUSE Filamin-C 2.882748 
ANXA3_MOUSE Annexin A3 2.876219 
TKT_MOUSE Transketolase 2.855865 
Q4FJQ6_MOUSE 
Serine (Or cysteine) peptidase inhibitor, clade B, member 6a, 
isoform CRA_a 2.822981 
Q6YJU1_MOUSE Fetuin-B 2.779361 
PYRD_MOUSE Dihydroorotate dehydrogenase (quinone), mitochondrial 2.772408 
DNJB4_MOUSE DnaJ homolog subfamily B member 4 2.739464 
HSPB2_MOUSE Heat shock protein beta-2 2.739235 
OLA1_MOUSE Obg-like ATPase 1 2.72664 
A2AIW9_MOUSE Mitochondrial-processing peptidase subunit alpha 2.687923 
Q5SUC3_MOUSE Calnexin 2.665787 
B1AX58_MOUSE Plastin-3 2.637293 
Q3TJY2_MOUSE WD repeat domain 1 2.619171 
D9J302_MOUSE ENH isoform 1e 2.592252 
HDHD2_MOUSE 
Haloacid dehalogenase-like hydrolase domain-containing protein 
2 2.579931 
Q3UCD9_MOUSE Cathepsin D 2.520039 
Q5SW88_MOUSE Protein Rab1a 2.514497 




A0A0H2UH17_MOUSE Ubiquitin associated protein 2-like, isoform CRA_b 2.497335 
B2RTM0_MOUSE Histone H4 2.495948 
Q5M9J2_MOUSE Histidine triad nucleotide binding protein 2 2.442678 
ATOX1_MOUSE Copper transport protein ATOX1 2.436779 
Q91XH5_MOUSE Sepiapterin reductase 2.39974 
MIRO1_MOUSE Isoform 4 of Mitochondrial Rho GTPase 1 2.379248 
PP1B_MOUSE Serine/threonine-protein phosphatase PP1-beta catalytic subunit 2.369575 
Q3U4U6_MOUSE T-complex protein 1 subunit gamma 2.3335 
A0A0R4J093_MOUSE UMP-CMP kinase 2.320654 
QCR10_MOUSE Cytochrome b-c1 complex subunit 10 2.277176 
COX7C_MOUSE Cytochrome c oxidase subunit 7C, mitochondrial 2.270833 
CAND1_MOUSE Cullin-associated NEDD8-dissociated protein 1 2.261506 
Q543M7_MOUSE Importin subunit alpha 2.232002 
Q8BVQ9_MOUSE 26S protease regulatory subunit 7 2.208435 
STIP1_MOUSE Stress-induced-phosphoprotein 1 2.197041 
TXD17_MOUSE Thioredoxin domain-containing protein 17 2.165337 
Q9CPX4_MOUSE Ferritin 2.161834 
F8WIA1_MOUSE CAP-Gly domain-containing linker protein 1 2.122414 
SDCG8_MOUSE Serologically defined colon cancer antigen 8 homolog 2.121559 
Q8BFQ1_MOUSE Prosaposin 2.119551 
PDIA6_MOUSE Protein disulfide-isomerase A6 2.068221 
Q499X4_MOUSE Synaptic vesicle membrane protein VAT-1 homolog 2.05867 
Q561N5_MOUSE 40S ribosomal protein S18 2.053017 
ES1_MOUSE ES1 protein homolog, mitochondrial 2.051459 
Q3U6L3_MOUSE Glutaredoxin, isoform CRA_a 2.049559 
PSA6_MOUSE Proteasome subunit alpha type-6 2.049024 
NDUC2_MOUSE NADH dehydrogenase 1 subunit C2 2.047106 
H7BX64_MOUSE Sarcolemmal membrane-associated protein 2.045809 
CO6A1_MOUSE Collagen alpha-1(VI) chain 2.038665 
COMT_MOUSE Catechol O-methyltransferase 2.035218 
ANXA7_MOUSE Annexin A7 2.034 
NDUS3_MOUSE NADH dehydrogenase iron-sulfur protein 3, mitochondrial 2.0308 
Q545S0_MOUSE Sulfurtransferase 2.007492 
UGPA_MOUSE UTP--glucose-1-phosphate uridylyltransferase 2.00286 
G5E8T9_MOUSE Hydroxyacyl glutathione hydrolase 1.99599 
GTR4_MOUSE Solute carrier family 2, facilitated glucose transporter member 4 1.990184 
PDC6I_MOUSE Programmed cell death 6-interacting protein 1.981432 
ANXA5_MOUSE Annexin A5 1.964818 
MAOX_MOUSE NADP-dependent malic enzyme 1.933061 
CD47_MOUSE Leukocyte surface antigen CD47 1.93226 
Q3TV21_MOUSE Frataxin 1.929493 
ODB2_MOUSE 
Lipoamide acyltransferase component of branched-chain alpha-
keto acid dehydrogenase complex, mitochondrial 1.928248 
VAPA_MOUSE Vesicle-associated membrane protein-associated protein A 1.90772 




NDUAD_MOUSE NADH dehydrogenase 1 alpha subcomplex subunit 13 1.890973 
MCAT_MOUSE Mitochondrial carnitine/acylcarnitine carrier protein 1.889925 
BACH_MOUSE Isoform C of Cytosolic acyl coenzyme A thioester hydrolase 1.876667 
Q5ND36_MOUSE Alpha-2-antiplasmin 1.863565 
F2Z456_MOUSE NADH-cytochrome b5 reductase 1.861127 
HSPB6_MOUSE Heat shock protein beta-6 1.847715 
COF1_MOUSE Cofilin-1 1.828459 
PLIN4_MOUSE Perilipin-4 1.827155 
Q5HZK3_MOUSE Proteasome (Prosome, macropain) 28 subunit, alpha 1.816172 
E9Q1W0_MOUSE Calcium/calmodulin-dependent protein kinase type II subunit delta 1.814084 
SYDC_MOUSE Aspartate--tRNA ligase, cytoplasmic 1.807108 
E9PUD2_MOUSE Dynamin-1-like protein 1.799964 
Q3TX38_MOUSE Voltage-dependent anion-selective channel protein 3 1.778391 
B3AT_MOUSE Band 3 anion transport protein 1.77496 
Q542G9_MOUSE Annexin 1.772496 
Q80Y52_MOUSE Heat shock protein 90, alpha (Cytosolic), class A member 1 1.764213 
LAMP2_MOUSE Lysosome-associated membrane glycoprotein 2 1.761354 
B7ZCF1_MOUSE 26S protease regulatory subunit 6A 1.743877 
Q497I3_MOUSE Fatty acid binding protein 5, epidermal 1.740813 
Q3TPZ5_MOUSE Dynactin 2 1.713427 
OXND1_MOUSE Oxidoreductase NAD-binding domain-containing protein 1 1.710108 
TBA8_MOUSE Tubulin alpha-8 chain 1.694346 
BZW2_MOUSE Basic leucine zipper and W2 domain-containing protein 2 1.690544 
VWA8_MOUSE von Willebrand factor A domain-containing protein 8 1.690259 
NDRG2_MOUSE Protein NDRG2 1.671721 
Q544D4_MOUSE Delta-sarcoglycan 1.671108 
GSTO1_MOUSE Glutathione S-transferase omega-1 1.670085 
BAG3_MOUSE BAG family molecular chaperone regulator 3 1.664661 
E9Q3X0_MOUSE Major vault protein 1.661372 
PSMD6_MOUSE 26S proteasome non-ATPase regulatory subunit 6 1.649079 
Q7JCZ1_MOUSE Cytochrome c oxidase subunit 2 1.648254 
NDUB2_MOUSE 
NADH dehydrogenase 1 beta subcomplex subunit 2, 
mitochondrial 1.645909 
Q8CBB6_MOUSE Histone H2B 1.645206 
NDUA6_MOUSE NADH dehydrogenase 1 alpha subcomplex subunit 6 1.643343 
Q4FJU3_MOUSE Crip2 protein 1.642117 
CATB_MOUSE Cathepsin B 1.640215 
ETHE1_MOUSE Persulfide dioxygenase ETHE1, mitochondrial 1.634732 
B0QZL1_MOUSE Alpha-enolase  1.633795 
Q6GT24_MOUSE Peroxiredoxin 6 1.626017 
TIM13_MOUSE Mitochondrial import inner membrane translocase subunit Tim13 1.615049 
Q3T9Z2_MOUSE Glyoxylate reductase/hydroxypyruvate reductase 1.610213 
G5E8R3_MOUSE Pyruvate carboxylase 1.597556 
NDUS2_MOUSE NADH dehydrogenase iron-sulfur protein 2, mitochondrial 1.596723 




KAD1_MOUSE Adenylate kinase isoenzyme 1 1.593473 
ATAD3_MOUSE ATPase family AAA domain-containing protein 3 1.586299 
NDUV2_MOUSE NADH dehydrogenase flavoprotein 2, mitochondrial 1.569232 
GDIR1_MOUSE Rho GDP-dissociation inhibitor 1 1.563698 
Q9MD82_MOUSE NADH-ubiquinone oxidoreductase chain 5 1.562489 
A2RTT4_MOUSE MCG4297 1.558157 
ENOB_MOUSE Beta-enolase 1.554284 
Q3TS44_MOUSE Proteasome subunit alpha type 1.552829 
G3X9J1_MOUSE Sodium/calcium exchanger 1 1.550129 
ARPC2_MOUSE Actin-related protein 2/3 complex subunit 2 1.542713 
GRPE1_MOUSE GrpE protein homolog 1, mitochondrial 1.538649 
Q91V77_MOUSE Protein S100 1.537994 
F6WYM0_MOUSE Septin-2  1.530294 
HSPB1_MOUSE Heat shock protein beta-1 1.52291 
TLN1_MOUSE Talin-1 1.52168 
Q545X8_MOUSE 40S ribosomal protein S4 1.519066 
A0A087WS46_MOUSE Elongation factor 1-beta 1.514587 
B9EHN0_MOUSE Ubiquitin-activating enzyme E1, Chr X 1.514322 
A0A0G2JFH2_MOUSE Microtubule-associated protein  1.510462 
Q9DCY1_MOUSE Peptidyl-prolyl cis-trans isomerase 1.504742 
 
Table 3.6   
Group C: Down-regulated Proteins KO-TAC vs KO-SHAM 
Uniprot accession Protein Fold Change 
NDUA3_MOUSE NADH dehydrogenase 1 alpha subcomplex subunit 3 7.130738 
DHSD_MOUSE 
Succinate dehydrogenase cytochrome b small subunit, 
mitochondrial 5.199991 
A1BG_MOUSE Alpha-1B-glycoprotein 4.615402 
CXA1_MOUSE Gap junction alpha-1 protein 4.604655 
NDUB3_MOUSE NADH dehydrogenase 1 beta subcomplex subunit 3 2.99022 
68MP_MOUSE 6.8 kDa mitochondrial proteolipid 2.836409 
Q8BTU6_MOUSE Eukaryotic initiation factor 4A-II 2.696546 
G5E8J6_MOUSE Histidine rich calcium binding protein, isoform CRA_a 2.535813 
Q58E35_MOUSE 60S acidic ribosomal protein P1 2.5039 
RL8_MOUSE 60S ribosomal protein L8 2.355288 
A1AT4_MOUSE Alpha-1-antitrypsin 1-4 2.341611 
FRIH_MOUSE Ferritin heavy chain 2.261752 
ILK_MOUSE Integrin-linked protein kinase 2.200704 
Q6P5I3_MOUSE S-(hydroxymethyl)glutathione dehydrogenase 2.184623 
RLA2_MOUSE 60S acidic ribosomal protein P2 2.169577 
NDUB4_MOUSE NADH dehydrogenase 1 beta subcomplex subunit 4 2.161729 
2AAA_MOUSE 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory 




Q497X4_MOUSE Cathepsin R 2.131074 
Q3U367_MOUSE 4-trimethylaminobutyraldehyde dehydrogenase 2.036147 
Q3UX28_MOUSE Brain protein 44-like 2.023577 
K22O_MOUSE Keratin, type II cytoskeletal 2 oral 1.984574 
Q91VA7_MOUSE Isocitrate dehydrogenase [NAD] subunit, mitochondrial 1.982698 
Q544X6_MOUSE Ferrochelatase 1.94918 
E9QMK9_MOUSE Protein 9030617O03Rik 1.948365 
MTX2_MOUSE Metaxin-2 1.925818 
E9Q7L0_MOUSE Protein Ogdhl 1.919471 
KV3A4_MOUSE Ig kappa chain V-III region 50S10.1 1.917761 
TRAP1_MOUSE Heat shock protein 75 kDa, mitochondrial 1.910707 
RL14_MOUSE 60S ribosomal protein L14 1.89362 
APOH_MOUSE Beta-2-glycoprotein 1 1.887297 
B1AU25_MOUSE Apoptosis-inducing factor 1, mitochondrial 1.839261 
Q921R2_MOUSE 40S ribosomal protein S13 1.827666 
ARF5_MOUSE ADP-ribosylation factor 5 1.821445 
MYL6_MOUSE Myosin light polypeptide 6 1.812493 
CES1D_MOUSE Carboxylesterase 1D 1.801977 
Q497F1_MOUSE Troponin I, cardiac 3 1.796747 
ABCB8_MOUSE ATP-binding cassette sub-family B member 8, mitochondrial 1.787346 
PPIF_MOUSE Peptidyl-prolyl cis-trans isomerase F, mitochondrial 1.75551 
LDHB_MOUSE L-lactate dehydrogenase B chain 1.730964 
DYL2_MOUSE Dynein light chain 2, cytoplasmic 1.729737 
IVD_MOUSE Isovaleryl-CoA dehydrogenase, mitochondrial 1.698572 
Q58EV5_MOUSE High mobility group box 1 1.66142 
ADCK3_MOUSE Atypical kinase ADCK3, mitochondrial 1.616159 
Q3TGZ3_MOUSE Isocitrate dehydrogenase [NAD] subunit, mitochondrial 1.608976 
CAD13_MOUSE Cadherin-13 1.603548 
Q6ZWZ6_MOUSE 40S ribosomal protein S12 1.601422 
B2RS41_MOUSE Aldhehyde dehydrogenase family 5, subfamily A1 1.598923 
RM12_MOUSE 39S ribosomal protein L12, mitochondrial 1.596099 
PLIN5_MOUSE Perilipin-5 1.58571 
RTN3_MOUSE Reticulon-3 1.555692 
SDHA_MOUSE Succinate dehydrogenase flavoprotein subunit, mitochondrial 1.534129 
TPM1_MOUSE Tropomyosin alpha-1 chain 1.52837 
 
Table 3.7 
Group D: Up-regulated Proteins in KO-TAC vs WT-TAC 
Uniprot Accession Protein Fold Change 
Q542X7_MOUSE Chaperonin subunit 2 (Beta), isoform CRA_a  4.011262 
QCR10_MOUSE Cytochrome b-c1 complex subunit 10  2.610662 




PSMD6_MOUSE 26S proteasome non-ATPase regulatory subunit 6  2.527684 
NDUF4_MOUSE NADH dehydrogenase  1 alpha subcomplex assembly factor 4  2.488534 
Q91XH5_MOUSE Sepiapterin reductase  2.382154 
Q9CPX4_MOUSE Ferritin  2.220084 
NDUC2_MOUSE NADH dehydrogenase  1 subunit C2  2.129968 
GTR4_MOUSE glucose transporter member 4  2.048086 
NDUA6_MOUSE NADH dehydrogenase  1 alpha subcomplex subunit 6  2.046164 
Q5M9J2_MOUSE Histidine triad nucleotide binding protein 2  2.004136 
CD47_MOUSE Leukocyte surface antigen CD47  1.993659 
Q8BH80_MOUSE Vesicle-associated membrane protein, associated protein B and C  1.94817 
A3KGQ6_MOUSE Actin-related protein 2/3 complex subunit 5  1.892679 
QCR8_MOUSE Cytochrome b-c1 complex subunit 8  1.850327 
NDUV2_MOUSE NADH dehydrogenase  flavoprotein 2, mitochondrial  1.801866 
NDUS3_MOUSE NADH dehydrogenase  iron-sulfur protein 3, mitochondrial  1.794648 
Q80ZZ0_MOUSE EH domain-containing protein 1  1.786371 
TM14C_MOUSE Transmembrane protein 14C  1.77977 
Q5SW88_MOUSE Protein Rab1a  1.767473 
CATB_MOUSE Cathepsin B  1.757032 
NDUAD_MOUSE NADH dehydrogenase  1 alpha subcomplex subunit 13  1.752319 
THIM_MOUSE 3-ketoacyl-CoA thiolase, mitochondrial  1.74534 
Q7JCZ1_MOUSE Cytochrome c oxidase subunit 2  1.739015 
Q4FK74_MOUSE ATP synthase subunit delta, mitochondrial  1.726552 
OXND1_MOUSE Oxidoreductase NAD-binding domain-containing protein 1  1.715566 
Z4YK42_MOUSE NAD kinase 2, mitochondrial  1.703483 
Q5NCJ9_MOUSE Cytochrome b-c1 complex subunit 9  1.680291 
CY1_MOUSE Cytochrome c1, heme protein, mitochondrial  1.673262 
B2RTM0_MOUSE Histone H4  1.663071 
Q792A4_MOUSE Cox7ah  1.659221 
CPT2_MOUSE Carnitine O-palmitoyltransferase 2, mitochondrial  1.658698 
Q8C5G6_MOUSE Toll-interacting protein  1.640463 
A0A0R3P9C8_MOUSE NADH dehydrogenase  1 alpha subcomplex subunit 9, mitochondrial  1.637799 
VWA8_MOUSE von Willebrand factor A domain-containing protein 8  1.63688 
Q4FJU3_MOUSE Crip2 protein  1.623828 
TACO1_MOUSE Translational activator of cytochrome c oxidase 1  1.604731 
HHATL_MOUSE Protein-cysteine N-palmitoyltransferase HHAT-like protein  1.593732 
HCDH_MOUSE Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial  1.580108 
F6TCV0_MOUSE Serine protease HTRA2, mitochondrial   1.580029 
Q9MD82_MOUSE NADH-ubiquinone oxidoreductase chain 5  1.575971 
RTN2_MOUSE Isoform 2 of Reticulon-2  1.57565 
Q3UAI3_MOUSE CD36 antigen, isoform CRA_a  1.563316 






Table 3.8  
Group D: Down-regulated Proteins in KO-TAC vs WT-TAC 
Uniprot Accession Protein Fold Change 
TBB5_MOUSE Tubulin beta-5 chain  2.981927 
DHSD_MOUSE Succinate dehydrogenase  cytochrome b small subunit, mitochondrial  2.481798 
F6ZFU0_MOUSE Elongation factor 1-delta   2.425279 
Q8BFQ1_MOUSE Prosaposin 2.378969 
CAH2_MOUSE Carbonic anhydrase 2  2.376344 
GCAM_MOUSE Ig gamma-2A chain C region, membrane-bound form  2.374465 
APOH_MOUSE Beta-2-glycoprotein 1  2.372747 
NDUA3_MOUSE NADH dehydrogenase  1 alpha subcomplex subunit 3  2.266877 
68MP_MOUSE 6.8 kDa mitochondrial proteolipid  2.150122 
CAH1_MOUSE Carbonic anhydrase 1  2.136464 
RL8_MOUSE 60S ribosomal protein L8  2.089221 
Q52L67_MOUSE Gpsn2 protein  2.083124 
Q544X6_MOUSE Ferrochelatase  2.051581 
B2RXX9_MOUSE Myosin, heavy polypeptide 7, cardiac muscle, beta  2.026056 
ARF5_MOUSE ADP-ribosylation factor 5  1.889291 
E9QLZ9_MOUSE Protein enabled homolog  1.845804 
Q545I9_MOUSE Protein S100  1.809239 
Q921R2_MOUSE 40S ribosomal protein S13  1.805659 
MTX2_MOUSE Metaxin-2  1.787365 
A2AEX8_MOUSE Four and a half LIM domains 1, isoform CRA_b  1.778477 
K22O_MOUSE Keratin, type II cytoskeletal 2 oral  1.770453 
Q6P5I3_MOUSE S-(hydroxymethyl)glutathione dehydrogenase  1.725549 
Q91VB8_MOUSE Alpha globin 1  1.700586 
E9Q616_MOUSE Protein Ahnak  1.698923 
TPM1_MOUSE Tropomyosin alpha-1 chain  1.659611 
B2MWM9_MOUSE Calreticulin  1.6296 
2AAA_MOUSE 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A 
alpha isoform  1.591433 
Q497F1_MOUSE Troponin I, cardiac 3  1.588601 
PLAK_MOUSE Junction plakoglobin  1.587987 
Q543J5_MOUSE Antithrombin  1.53439 
CO3_MOUSE Complement C3  1.530253 
MLRV_MOUSE Myosin regulatory light chain 2, ventricular/cardiac muscle isoform  1.528094 
DYL2_MOUSE Dynein light chain 2, cytoplasmic  1.52776 
TMOD1_MOUSE Tropomodulin-1  1.517943 
Q549A5_MOUSE Clusterin  1.516287 





Fig. 3.17. Distribution of identified proteins in global proteome analysis: A-D Volcano plots illustrating the proteomic 
data log2 fold-change (log2 FC) on X axis and statistical significance distribution log10 of p values (-log10 (p-value)) on 
Y-axis of the proteomic data. Data points in red and green indicate proteins defined to be significantly differentially 
expressed based upon 1.5-fold change and p value of 0.005. Proteins in red denote those that reached statistical 
significance using Welch’s T-test and are up-regulated while Proteins in green shows significant down-regulation. 
 
3.6.2 Functional characterization of proteome data using STRING analysis 
For detailed characterization of proteome, we used STRING analysis to categorize 
differentially expressed proteins according to their subcellular localization as assigned by 






3.6.2.1 Characterization of Group A (WT-SHAM vs KO-SHAM) proteome 
Previously, we observed in PCA plot (Fig. 3.15) that WT-SHAM and KO-SHAM are closely 
clustered to each other showing less variability. Perseus analysis showed there were only 
8 up-regulated proteins in KO-SHAM as compared to WT-SHAM while there were 58 down-
regulated proteins. We analysed these up and down- regulated proteins using STRING 
analysis. We observed 5 proteins belonging to (cytosol, 63%) while 3 proteins belong to 
mitochondria (37%) in KO-SHAM (Fig. 3.18A). Up-regulated proteins are showing a small 
cluster of mitochondrial proteins based on their function and localisation while cytoplasmic 
proteins are not showing any significant link (Fig. 3.18B). Similarly, we observed out of 58 
down-regulated proteins in KO-SHAM, 73% proteins belonging to cytoplasm, 17% proteins 
to cytoskeleton while 10% to ribosome in (Fig. 3.18C). The STRING analysis revealed a 
functional link between down-regulated proteins in KO-SHAM based on their function and 
localisation one cluster of proteins belong to ribosomal proteins (Fig. 3.18D). Some other 










Fig. 3.18. Characterization for Group A, WT-SHAM vs KO-SHAM proteome. Pie chart shows proteins according to 
their subcellular location assigned by STRING and Gene-ontology (GO). Percentage of up-regulated proteins (A) and 
down-regulated proteins (C), Orange colour shows localised in cytoplasm, blue colour represents proteins localised in 
mitochondria, yellow colour represents ribosomal proteins and grey colour represents cytoskeleton proteins. Analysis of 
protein interaction network by STRING (B & D), Coloured lines between the proteins indicate the protein co-occurrence, 
co-expression, known interactions and predicted interactions. Up-regulated proteins do not present any specific 
interaction or cluster (B) however Interconnecting ribosomal proteins (red circle) represents a functionally associated 









3.6.2.2 Characterization of Group B (WT-SHAM vs WT-TAC) proteome 
Next, we analysed group B: WT-SHAM comparison with WT-TAC. Previously, we 
observed in PCA plot (Fig. 3.15) that WT-SHAM and WT -TAC are showing clusters 
variability which would be interesting to analyse. Perseus analysis showed there were 60 
up-regulated and 70 down-regulated proteins in WT-TAC as compared to WT-SHAM. 
Fig. 3.19. Characterization for Group B, WT-SHAM vs WT-TAC proteome. Pie chart shows proteins according to their 
subcellular location assigned by STRING and Gene-ontology (GO). %age of up-regulated proteins (A) and down-
regulated proteins (C), Orange colour shows proteins localised in cytoplasm, blue colour represents the mitochondrial, 
green colour represents contractile fibre associated proteins, grey colour represents cytoskeleton proteins, purple colour 
represents vesicle associated proteins and yellow colour represents ribosomal associated proteins. Analysis of protein 
interaction network by STRING (B & D), Coloured lines between the proteins indicate the protein co-occurrence, co-
expression, known interactions and predicted interactions. Up-regulated proteins show interconnecting mitochondrial 
proteins (blue circle) represents a functionally associated protein cluster, while cytoskeleton associated proteins are 







represents a functionally associated protein cluster, while ribosomal associated proteins are showing another cluster (red 
circle) in down-regulated proteins (D). B and D full view available as Supplementary Fig. S2 and S3 respectively. 
 
We further analysed these up and down- regulated proteins using STRING analysis. We 
observed out of 60 up-regulated proteins in WT-TAC, 51% proteins belonging to 
cytoplasm, 19% to mitochondrial, 17% proteins to cytoskeleton while 13% to contractile 
fibre proteins (Fig. 3.19A). The STRING analysis revealed functional link between up-
regulated proteins in WT-TAC, based on their function and localisation. One cluster of 
proteins (blue circle) belong to mitochondrial proteins while second cluster (grey circle) 
represents cytoskeleton associated proteins (Fig. 3.19B). Some other proteins are also 
linked but they do not form a major interconnecting cluster. Most of them are multiple 
enzymes either involved in translocation of molecules or associated with different 
metabolic pathways. Similarly, we observed out of 70 down-regulated proteins in WT-TAC, 
44% proteins belonging to cytoplasm, 45% proteins to mitochondria, 8% to vesicles while 
3% to ribosome in (Fig. 3.19C). Interestingly, majority of down-regulated proteins are linked 
to mitochondria in WT-TAC. The STRING analysis revealed functional link between down-
regulated proteins in WT-TAC, based on their function and localisation. One major cluster 
of proteins (blue circle) belong to mitochondrial proteins while second cluster (red circle) 
represents Ribosomal associated proteins (Fig. 3.19D). Some other proteins are also 
linked but they do not form a major interconnecting cluster. Most of them are multiple 
enzymes which are associated with different metabolic pathways.  
3.6.2.3 Characterization of Group C (KO-SHAM vs KO-TAC) proteome 
Next, we analysed group C, KO-SHAM comparison with KO-TAC. Previously, we observed 
in PCA plot (Fig. 3.15) that KO-SHAM and KO -TAC are showing clusters variability which 
would be interesting to analyse. Perseus analysis showed there were 150 up-regulated 
and 53 down-regulated proteins in KO-TAC as compared to KO-SHAM. We further 
analysed these up and down-regulated proteins using STRING analysis. We observed out 
of 150 up-regulated proteins in KO-TAC, 40% proteins belonging to cytoplasm, 28% to 
vesicles, 17% to mitochondrial, 13% proteins to cytoskeleton while 2% to proteasome 
associated proteins (Fig. 3.20A). The STRING analysis revealed functional link between 




proteins (blue circle) belong to mitochondrial proteins while second cluster (green circle) 
represents proteasome- 
Fig. 3.20. Characterization for Group C, KO-SHAM vs KO-TAC proteome. Pie chart shows proteins according to their 
subcellular location assigned by STRING and Gene-ontology (GO). % of up-regulated proteins (A) and down-regulated 
proteins (C), Orange colour shows proteins localised in cytoplasm, blue colour represents the mitochondrial, green colour 
represents contractile fibre associated proteins, grey colour represents cytoskeleton proteins, purple colour represents 
vesicle associated proteins, Light-green colour represents proteasome associated proteins and yellow colour represents 
ribosomal associated proteins. Analysis of protein interaction network by STRING (B& D), Coloured lines between the 
proteins indicate the protein co-occurrence, co-expression, known interactions and predicted interactions. Up-regulated 
proteins show interconnecting major cluster (red circle) represents multiple enzymes involved in metabolic pathways and 










cluster, while proteasome associated proteins are showing another cluster (green circle) (B). Interconnecting major 
clusters show mitochondrial proteins (blue circle), ribosomal proteins (yellow circle) and cytoskeleton proteins (grey 
circle) in down-regulated proteins (D). B and D full view available as Supplementary Fig. S4 and S5 respectively. 
 
-associated proteins (Fig. 3.20B), Interestingly third major cluster have proteins which are 
mainly enzymes either involved in translocation of molecules or associated with different 
metabolic pathways and some cytoskeleton associated proteins. In down-regulated 
proteins we observed out of 53 proteins in KO-TAC, 47% proteins belonging to cytoplasm, 
30% proteins to mitochondria, 19 % to ribosome while 8% to cytoskeleton (Fig. 3.20C). 
The STRING analysis revealed functional link between down-regulated proteins in KO-
TAC, based on their function and localisation. Two clusters of proteins (blue circle) belong 
to mitochondrial proteins, one cluster (yellow circle) associated with ribosomal proteins 
while one small cluster (grey circle) represents cytoskeleton associated proteins (Fig. 
3.20D). 
3.6.2.4 Characterization of Group D (WT-TAC vs KO-TAC) proteome  
Next, we analysed group D, WT-TAC comparison with KO-TAC. Previously, we observed 
in PCA plot (Fig. 3.15) that WT-TAC and KO -TAC are showing clusters variability which 
would be interesting to analyse. Perseus analysis showed there were 43 up-regulated and 
36 down-regulated proteins in KO-TAC as compared to WT-TAC. We further analysed 
these up and down- regulated proteins using STRING analysis. We observed out of 43 up-
regulated proteins in KO-TAC, 47% proteins belonging to cytoplasm, 33% to mitochondrial, 
while 20% to vesicles associated proteins (Fig. 3.21A). The STRING analysis revealed 
functional link between up-regulated proteins in KO-TAC, based on their function and 
localisation. One major cluster of proteins (blue circle) belong to mitochondrial proteins 
(Fig. 3.21B). We observed out of 36 down-regulated proteins in KO-TAC, 39% proteins 
belonging to cytoplasm, 22% to vesicle associated, 21% to cytoskeleton, 10% proteins to 
mitochondria and 8 % to ribosome (Fig. 3.21C). The STRING analysis revealed functional 
link between down-regulated proteins in KO-TAC, based on their function and localisation. 
One cluster (yellow circle) associated with ribosomal proteins while one small cluster (grey 




Fig. 3.21. Characterization for Group D, WT-TAC vs KO-TAC proteome. Pie chart shows proteins according to their 
subcellular location assigned by STRING and Gene-ontology (GO). % of up-regulated proteins (A) and down-regulated 
proteins (C), Orange colour shows proteins localised in cytoplasm, blue colour represents the mitochondrial, green colour 
represents contractile fibre associated proteins, grey colour represents cytoskeleton proteins, purple colour represents 
vesicle associated proteins, and yellow colour represents ribosomal associated proteins. Analysis of protein interaction 
network by STRING, Coloured lines between the proteins indicate the protein co-occurrence, co-expression, known 
interactions and predicted interactions. Up-regulated proteins show Interconnecting major cluster shows mitochondrial 
proteins (blue circle) (B). Interconnecting major clusters show ribosomal proteins (yellow circle) and cytoskeleton proteins 









Interestingly in our data, group D (WT-TAC/KO-TAC) up-regulated proteins were 
associated with mitochondrial function in functional annotation and in cluster analysis (Fig. 
3.19B). We further investigated the proteins which were associated with mitochondria and 
found out NADH dehydrogenase complex (Complex I of ETC) proteins were dominating 
the cluster (Fig. 3.19B). It is interesting to note that mitochondrial Complex I deficiency in 
the mouse heart results in severe hypertrophic cardiomyopathy due to selective loss of 
Ndufs4 (Chouchani et al., 2014). We found 9 out of 45 subunits of Complex I to be up-
regulated in KO-TAC mice. 
3.6.3 Ingenuity Pathway Analysis (IPA) for significantly differentiated proteins 
in Group C and D  
Then we concentrated more on KO-TAC vs KO-SHAM (Group C) and KO-TAC vs. WT-
TAC (Group D) groups to identify signalling pathways that are differentially regulated in 
KO-TAC hearts and might have been responsible for observed cardiac hypertrophy rescue.  
For this reason, we employed IPA tool, which confirmed that the identified proteins of KO-
TAC mice hearts are majorly associated with mitochondrial dysfunction (p-value 9.72e-13), 
Oxidative phosphorylation (p-value 6.44e-13), and Sirtuin signalling pathway (p-value 1.47e-
06) (Fig. 3.22A-B). Both STRING and IPA analyses highlighted increased number of 
proteins belongings to mitochondrial activity and oxidative phosphorylation in KO-TAC 
mice hearts. These analyses suggest that restored mitochondrial function might be a 
contributing factor in improved cardiac function. In order to verify this hypothesis, we made 
use of our in-vitro model of inflammation and investigated the effect of PTP1b inhibition on 




Fig. 3.22. Ingenuity pathway analysis (IPA) of KO-TAC vs WT-TAC proteins: A. Top Canonical Pathways displays 
the most significant Pathways across the entire dataset. The significance values of the canonical pathways were 
calculated by Fisher's exact test right-tailed. B. Stacked Bar chart plotted between -log of p-values (orange) and 
percentage are displaying the number of up-regulated (red), down-regulated (green) proteins, and orange square 
represents the -log of p-values of proteins from data set, in each Canonical Pathway. 
 
3.6.4 PTP1b Inhibition in HUVECs  
To inhibit the function of PTP1B in HUVECs we decided to use Claramine Sulphate, a 
known and commercially available inhibitor of PTP1B. To establish the concentration of 
Claramine required for efficient inhibition of PTP1B function, we treated HUVECs with 
different concentrations of Claramine (10, 50 and 100 μM) in four groups 1. Control - non-
treated cells, 2. TNF-α-only - cells were treated with 20ng/ml TNF-α for 2 hrs, 3. 





4. Claramine+TNF-α - cells were treated with either 10, 50 or 100 μM Claramine for 30 
mins followed by TNF-α treatment for 2 hrs. Cells were harvested after treatment and 
analysed for the expression levels of p-AKT, which is a target of PTP1B to confirm the 
inhibition of PTP1B function. TNF-α treated cells showed reduced expression of p-AKT, 
while 100 μM of Claramine-only showed significantly higher expression of p-AKT as 
compared to control cells (Fig. 3.23). When cells are treated with Claramine followed by 
TNF-α, there is no difference in expression of p-AKT as compared to non-treated control. 
This data indicates that PTP1B inhibition leads to increased phosphorylation in of AKT, 
however, TNF-α treatment reverses this phosphorylation to basal level. After successfully 
establishing the PTP1B inhibition model in HUVECs, we went on to study the role of PTP1B 












Fig. 3.23. PTP1B inhibition in HUVECs. Western Blot shows relative Protein expression of p-AKT normalised to house-
keeping β-actin then to AKT in Control, TNF-α-only, Claramine-only (10, 50, 100 μM) , Claramine (10, 50, 100 μM)+TNF-
α. Values are mean ± SEM of two biological replicates and asterisk indicate statistical significance of * p<0.05 compared 








3.6.5 Mitochondrial function assay 
To study the role of PTP1B in mitochondrial function, we treated HUVECs in five different 
groups 1. Control non-treated cells, 2. Claramine-only - cells treated with Claramine for 
30 min, 3: TNF-α-only - cells treated with 1500 units/ml of TNF-α for 6 hrs to induce 
mitochondrial dysfunction, 4: Claramine+TNF-α – in which cells were pre-treated with 
Claramine for 30 min followed by TNF-α for 6 hrs and 5: Mitochondrial toxin - cells treated 
with Sodium Azide 100 μM as a positive control of mitochondrial toxicity. Thereafter, 
Cytotoxicity and ATP production was measured by using Mitochondrial ToxGlo™ Assay kit 
(Promega). 
The Mitochondrial ToxGlo™ Assay is a live cell-based assay that measures mitochondrial 
dysfunction. The assay detects the changes in cell membrane integrity and cellular ATP 
levels. Firstly, cell membrane integrity is analysed via detection of dead cell protease 
activity. If treatments are cytotoxic then the added fluorogenic peptide can cross the cell 
membrane and give significant signal as compared to viable cells of control. Next, ATP 
detection reagent is used to lyse the cells and generate a luminescent signal. To minimise 
the ATP production from glycolysis, all treatments were done in DMEM containing 
Galactose and in the absence of serum to avoid Glucose. Our data showed that there is a 
reduced ATP production when cells were treated with TNF-α or Positive control- 
mitochondrial toxin, highlighting the mitochondrial dysfunction during inflammatory 
response. However, pre-treatment with PTP1B inhibitor, Claramine, protects HUVECs 
from TNF-α induced mitochondrial dysfunction (Fig. 3.24). In parallel, cytotoxicity was 
measured, which indicated no significant difference among various treatments, indicating 
that the observed depletion of ATP, especially in TNF-α treatment, is not due to necrosis, 














Fig. 3.24. Evaluation of mitochondrial toxicity in in-vitro inflammatory model. HUVECs were treated in following 
groups as 1. not-treated control, 2. Claramine only-, TNF-α-only-, Claramine+TNF-α and Mitochondrial toxin (Sodium 
Azide). The percentage of Cytotoxicity (pink) and ATP production (orange) was measured by using Mitochondrial ToxGlo 
kit (Promega). Values are mean ± SEM of two biological replicates and asterisks indicate statistical significance of *** p< 
0.001, and * p<0.05.  
 
Our data showed that KO-TAC heart improved cardiac function after deletion of endothelial 













Atherosclerosis, a chronic inflammatory disorder of vascular system, is one of the major 
contributing cause in development and progression of CVDs including coronary artery 
disease and heart attack (Verstraete, 1990; Zampetaki et al., 2010). Inflammatory 
response can lead to ECs activation and dysfunction which is considered as initiative 
trigger in the development of atherosclerosis (Chien, 2008; Xiao et al., 2014). 
Hypertension, hyperglycemia, disturbed blood flow, hypercholesteremia, and inflammatory 
mediators in blood like LPS (secreted by microbes) and TNF-α (secreted by cells, in 
response to LPS) can initiate inflammatory response in ECs via activation of NF-κB (Fig. 
4.1) (Bleakley et al., 2015; Dart and Chin-Dusting, 1999; Hadi et al., 2005; Higashi et al., 
2012; Messner and Bernhard, 2014).  
 
Figure 4.1. Factors involved in ECs activation, inflammation, and in atherosclerotic plaque development Factors 
involved in ECs activation, inflammation, monolayer disruption and progression of atherosclerotic plaque development. 
Smoking, hypertension, hyperglycemia, and LPS secreted by bacteria can cause ECs injury which results in activation 
of NF-κB signalling pathway. Cytokines, chemokines and growth factor secreted by activated ECs participate in further 
the development of atherosclerotic plaque. 
 
Among these causative agents LPS and TNF-α, pro-inflammatory mediators, are used for 
establishing in-vitro inflammatory models. LPS and TNF-α lead to ECs activation, 
expression of adhesion molecules on ECs and activation of various signalling pathways 





which leads to CD14 dependent activation of Src-kinase which phosphorylates Caveolin-
1 (Cav-1) (Wong et al., 2004). Phosphorylated Cav-1 leads to formation of a complex 
including Interleukin receptor associated kinase 1 (IRAK1), (IRAK4) and Myeloid 
differentiation primary response 88 (MyD88) which leads to NF-κB signalling pathway 















Figure 4.2. LPS mediated NF-κB activation LPS activates TLR4 which leads to CD14 mediated activation of Src-
kinase which phosphorylates Cav-1. Phosphorylated Cav-1 leads to formation of IRAK1-IRAK4-MyD88 complex 
formation which leads to TRAF-6 based activation of IκB kinase which activates NF-κB signalling pathway (Figure 
published by Jiao et al., 2013). 
 
TNF-α, a proinflammatory cytokine, binds to ECs surface via tumor necrosis factor receptor 
(TNFR) and activates NF-κB signalling pathway via activation of IκB kinase. TNF-α 
stimulation leads to multiple changes leading to ECs dysfunction (Zhang et al., 2009). 
These changes include reduced eNO production, reduced ECs specific vasodilation and 





infiltration which contributes in the development of atherosclerosis (Fig. 4.3) (Zhang et al., 
2009).  
Nf-κB, a key mediator of inflammation, translocates from cytoplasm into nucleus and 
initiates transcription of pro-inflammatory markers (Brown et al., 2014; Xiao et al., 2014). 
Inflammatory markers include adhesion molecules like VCAM-I and SELE which are 
expressed on activated ECs and binds to monocytes (Gerhardt and Ley, 2015). Activated 
ECs also release cytokines like IL6 and IL8 which further recruits immune cells to ECs 
(Gerhardt and Ley, 2015; Ramji and Davies, 2015).  
Figure 4.3. TNF-α mediated NF-κB activation contributes in ECs dysfunction TNF-α activates TNFR which leads to 
activation of IκB kinase which activates NF-κB signalling pathway. Activated NF-κB contributes in inflammation and 
increases cellular infiltration across ECs monolayer (Figure adapted from Zhang et al., 2009). 
 
We used HUVECs as our in-vitro model for induction of inflammation in atherosclerosis 
and first to study the function of BRD4 in this model system. In agreement with the 
literature, HUVECs treated with TNF-α showed successful translocation of NF-κB into 
nucleus as compared to control cells. Our data shows significant increase of pro-
inflammatory markers SELE and VCAMI in HUVECs after TNF-α treatment. Together, 
localisation of NF-κB inside the nucleus and overexpression of pro-inflammatory markers 
confirms the establishment of inflammatory phenotype in HUVECs.  
BRD4 is an epigenetic factor and a member of transcription initiation machinery. It 
recognises and binds to the acetylated chromatin and recruit RNA polymerase to initiate 
transcription (Crowe et al., 2016; Devaiah et al., 2016; Devaiah et al., 2012). BRD4 is 





where BRD4 was reported as a partner of NF-κB on chromatin during inflammation (Xu 
and Vakoc, 2014a). To elaborate the role of BRD4 during inflammation, we used HUVECs 
as in-vitro model. We first used JQ1, a classical inhibitor of BRD4 to inhibit the function of 
BRD4. JQ1 binds to bromodomain I and II of BRD4 with hydrogen bonding interaction and 
blocks its ability to bind to acetylated chromatin (Bid and Kerk, 2016). We first treated the 
HUVECs with JQ1 followed by TNF-α treatment. Our data showed that pre-treatment with 
500 nM of JQ1 for 4 hrs significantly reduced the expression of inflammatory markers. We 
observed  1᷉0-fold and  1᷉7-fold reduction in expression of SELE and VCAM-I, respectively, 
as compared to TNF-α-only treated cells. These results are in support of previous studies 
that showed BRD4 binds to SE regions of pro-inflammatory genes along with NF-κB during 
inflammation. These results also indicate that the inhibition of BRD4 function reduces the 
expression of BRD4 and pro-inflammatory markers during inflammation.  
Further on our immunostaining data showed that inhibition of BRD4 function did not affect 
the subcellular localization of Nf-κB. These results confirm that JQ1 treatment does not 
affect the NF-κB translocation into the nucleus during inflammatory response and the 
observed reduced expression of inflammatory markers is due to inhibition of BRD4 
function.  
JQ1 is an efficient inhibitor of BRD4, however, it also interacts with other members of BET 
family (Huang et al., 2016; Huang et al., 2017). Short half-life of JQ1 also make it unsuitable 
for animal studies and clinical trials (Wadhwa and Nicolaides, 2016). Hence, we decided 
to analyse another inhibitor of BRD4, RVX208, which is orally active and was already in 
clinical trials for atherosclerosis, diabetes, Alzheimer’s disease, and chronic kidney 
disease (Picaud et al., 2013; Wadhwa and Nicolaides, 2016). It has been reported that 
RVX208 treatment increases the apolipoprotein A-I (Apo-A-I) and High-density cholesterol 
(HDL) in blood which reduces multiple adverse effects observed in cardiac patients (Ghosh 
et al., 2017). Interestingly, BRD4, but not BRD2 and BRD3, knockdown increases the 
mRNA levels of Apo-A-I confirming it as a target of BRD4 (Zengerle et al., 2015). 
Isothermal titration calorimetry studies on BET proteins with RVX208 showed 4-fold higher 
binding affinity of RVX208 to BRD4 as compared to other BET family members (Kempen 
et al., 2013).  
Collectively from literature review we know that RVX208 is a stable, orally active, already 




et al., 2016). Keeping these facts in mind, we decided to comparatively analyse effects of 
RVX208 and JQ1 in our studies. Previous studies have used variable concentrations of 
JQ1 for variable time points including 250 nM for 6 hrs (Huang et al., 2016), 500 nM for 3 
hrs (Huang et al., 2017), 500 nM for 4 hrs (Picaud et al., 2013), 500 nM for 24 hrs (Bid et 
al., 2016) and 1-2 μM of JQ1 for 24 hrs (Bid et al., 2016).  
As per our knowledge there are no studies reporting the RVX208 treatment on HUVECs. 
However, we found two studies on primary human hepatocytes which showed treatment 
with 30 μM RVX208 for 24 and 48 hrs for inhibition of BRD4 (Gilham et al., 2016; Wasiak 
et al., 2016). Another study on C11 macrophage cell line used 50 to 100 μM of RVX208 
for 72 hrs (Lu et al., 2017). In order to establish RVX208 concentration necessary to inhibit 
the inflammatory phenotype, we initially used different concentrations of RVX208 for 4 hrs 
which did not reduce the expression of inflammatory markers even at higher concentration 
of 200 μM. We treated HUVECs with 30 and 60 μM of RVX208 for 12-, 24- and 48-hrs 
followed by TNF-α for 12 hrs. We observed 12 hrs pre-treatment was significantly reducing 
the expression of pro-inflammatory marker. On the basis of these experiments, we treated 
HUVECs with 60 μM of RVX208 followed by 12 hrs TNF-α treatment for BRD4 inhibition. 
As we did not find any difference in 4 hrs and 12 hrs treatment with JQ1 we used 500 nM 
of JQ1 for 12 hrs followed by 12 hrs TNF-α treatment. 
Comparative analysis indicated that 12 hrs pre-treatment with RVX208 reduces the 
expression of SELE by 2.8-fold and of VCAM-1 and IL6 by 3-fold and 7-fold, respectively, 
as compared to TNF-α treatment. However, pre-treatment with JQ1 reduces the 
expression of SELE by 6-fold and of VCAM-1 and IL6 by 8-fold and 10-fold, respectively, 
as compared to TNF-α treatment. This indicates that both JQ1 and RVX208 could 
efficiently inhibit the inflammatory response, however, JQ1 is rather more efficient than 
RVX208, and the reason could be non-specific interaction of JQ1 with BRD2 and BRD3, if 
any (Bid and Kerk, 2016; Huang et al., 2016; Huang et al., 2017; Wadhwa and Nicolaides, 
2016; Zengerle et al., 2015). Interestingly, BRD4 is highly expressed in ECs as compared 
to BRD2 and BRD3 hence the results obtained with JQ1 might be directly attributable to 
BRD4 inhibition in these cells (Huang et al., 2016).  
Another interesting observation from our treatments was whenever we treat the cells with 
RVX208-only or JQ1-only we observed the reduction of VCAM-I and IL6 expression as 




and IL6 by 1.4-fold and 3-fold, respectively. Similarly, JQ1-only treatment reduces the 
expression of VCAM-I and IL6 by 2.5-fold and 2.3-fold, respectively. This data shows that 
BRD4 is also responsible for basal level gene expression of VCAM-I and IL6, therefore, in 
presence of only inhibitors basal level gene expression of these genes is also reduced. 
Brown et al. (2014) performed ChIP-Seq analysis and identified BRD4 binding on SEs of 









Figure 4.4 BRD4 genome binding in absence and presence of TNF-α. Heat maps showing gene track ChIP-seq 
signals for BRD4 (red) at VCAM-I loci untreated (top) and TNF-α treated (bottom). (Figure published by Brown et al., 
2014).  
 
In normal resting ECs, BRD4 binds at VCAM-I enhancer region and that binding increases 
upon treatment with TNF-α (Fig. 4.4). This evidence shows that BRD4 binds to SEs region 
of VCAM-I , and perhaps also on IL6, in resting ECs. This might be the reason for the 
observed reduced expression of both genes in RVX208-only and JQ1-only treated cells.  
BRD4 isoforms namely BRD4-long (BRD4-L) and BRD4-short (BRD4-S) are known for 
their differential roles in different diseases. In particular, over expression of BRD4-S is 
associated with enhanced metastasis in colon and breast cancers (Alsarraj et al., 2013; 
Hu et al., 2015). On the other hand, BRD4-L isoform has been reported to reduce 
metastasis (Alsarraj et al., 2013; Hu et al., 2015). Owing to these facts we were interested 
to determine the expression of BRD4 isoforms in normal as well as in inflammatory states 





in normal and inflammatory conditions, but also during BRD4 inhibition studies and in 
CVDs models like cardiac hypertrophy and aging hearts. 
Our data indicated that mRNA expression of BRD4-total was high when HUVECs are 
treated with TNF-α for 12 hrs. We wanted to investigate further that the increased 
expression of BRD4 during inflammatory stress is due to higher expression of BRD4-L or 
BRD4-S. We analyzed isoform specific mRNA expression and observed in case of 
inflammatory stimulus both isoforms have non-significant higher expression, however at 
protein levels we found short isoform to be significantly high during inflammatory stress. 
Moreover, we also observed BRD4-S high protein expression in cells which were pre-
treated with inhibitors followed by TNF-α treatment. As discussed previously that BRD4-S 
has been known for its role in enhancing cancer metastasis. Similarly, the observed 
increased expression of BRD4-S during inflammatory response in ECs may indicate its 
role in ECs dysfunction. However, further studies aimed at selective knock-down of BRD4 
isoforms are necessary to confirm these results. 
Similarly, when we treat cells with inhibitors-only we observed reduced expression of 
BRD4-total. These results indicate that BRD4 inhibitors not only inhibit the function of 
BRD4 but also reduce its expression suggesting auto-regulation of BRD4 expression. 
These results are in agreement with data of Wang et al. (2016) which reported suppression 
of BRD4 mRNA and protein expression in oral carcinoma cell line (Cal27), when treated 
with 500 nM to 1 μM of JQ1 (Wang et al., 2016). The reduced expression of BRD4-total in 
our system is due to reduced expression of BRD4-L at mRNA and protein levels. We 
observed higher expression of BRD4-L in HUVECs, hence we may conclude that JQ1 and 
RVX208 both effect BRD4-L levels in HUVECs probably because of its higher expression. 
Aging is a major non-modifiable risk factor, which contributes in progression of CVDs. Age-
specific cardiac remodelling includes left ventricle hypertrophy, fibrosis, cardiomyocytes 
lengthening, and deposition of ECM in cardiac tissues leads to multiple pathological 
cardiac conditions (Cheng et al., 2009; Mottonen et al., 2017). One interesting hallmark of 
age specific cardiac remodelling is isoform shift of Myosin heavy chains in heart. 
Embryonic heart mainly consists of β-MHC which converts to α-MHC in adult heart (Gupta, 
2007; Mahdavi et al., 1984). As the mammals age, β-MHC became dominant again (Gupta, 
2007). Similarly, in cardiac hypertrophy, α-MHC disappears, and β-MHC is dominantly 




in mind, we decided to analyse whether BRD4 isoforms have any role during cardiac 
remodelling due to aging and cardiac hypertrophy. The mRNA expression analysis of Brd4-
total, Brd4-L and Brd4-S did not show any significant differences in mice hearts of 1 to 18-
months-old except for 6-months-old mice heart, which showed significantly higher Brd4-S 
expression. Protein expression of BRD4-S was only detectable till 8-months old and BRD4-
L was significantly higher in 18-months-old mice hearts. However, further analysis on older 
than 18 months could further explain that whether BRD4-L isoform is high at old age or 
not. It is known that there is an increase in expression of inflammatory genes in pressure 
overloaded hearts (Chen et al., 2015; Souders et al., 2012). BRD4 inhibition reduces the 
expression of pro-fibrotic genes and have been recommended as a treatment of fibrosis 
(Stratton et al., 2017). In this context, we decided to analyse the expression of BRD4 
protein in cardiac fibrosis model of TAC mice. Our data showed that there is no significant 
expression difference in TAC and SHAM mice. This data may indicate that BRD4 isoforms 
expression may not vary during cardiac remodelling of hearts in hypertrophy or during 
aging process. 
ECs monolayer is classified as largest organ due to its active contribution in physiological 
pathways (Aird, 2004; Anggard, 1990). It acts as a barrier between blood and tissues and 
regulates immune system, transport of nutrients and growth of new vessels by secreting 
biologically active substances (Aird, 2004; Anggard, 1990). Inflammation, microbial 
infection, ROS and increased oxidative stress due to oxidized LDL in blood can cause ECs 
monolayer disruption and which can lead to progression of multiple diseases including 
atherosclerosis (Ji et al., 2015).  
We decided to analyse the effect of inflammatory stimulus on ECs barrier function in-vitro. 
HUVEC monolayers were established and were first treated with TNF-α to analyse the 
effect of inflammatory stimulus. We observed reduction in trans endothelial electric 
resistance, increase in permeability across the monolayer with 12 hrs of TNF-α treatment. 
These results support a previous study of Urbano et al. (2017), which reported increase of 
permeability across ECs with TNF-α treatment. Our data also indicate that whenever 
HUVECs were pre-treated with RVX208 or JQ1 followed by TNF-α treatment inhibited the 
barrier dysfunction. These results indicate that BRD4 inhibition is reducing the expression 





Huang et al. (2016) previously reported that JQ1 treatment reduced the VEGF-induced 
permeability by blocking p21-activated kinase-1 (PAK-1) and eNOS activation. From 
literature review we know that VEGFR2 is also responsible for activation of p38MAPK 
pathway and in line with this, Huang et al. (2017) in another study reported that JQ1 
treatment suppresses vascular inflammation via blocking of p38MAPK pathway. 
Interestingly, our group previously reported increased permeability in human epithelial 
colorectal adenocarcinoma cells (Caco-2 cells) is due to a cytokine Midkine, an upstream 
regulator of p38MAPK pathway (Khan et al., 2017). It has been reported that cytokines can 
modulate the cytoskeleton of ECs and open the gaps between adjacent cells which 
increase the permeability of ECs monolayers (Ramji and Davies, 2015). Among different 
cytokines, Midkine is an interesting target as it has been reported to be highly expressed 
in inflammatory kidney disease and atherosclerosis (Salaru et al., 2013; Salaru et al., 
2016).  
Based on these evidences, we decided to analyse Midkine expression in ECs monolayer 
in the presence of inflammatory stimuli. Our data showed increased expression of 
MIDKINE at mRNA level after 6 hrs of TNF-α treatment and it steadily increased until 72hrs 
of treatment. At protein level we observed MIDKINE to be secreted from HUVECs after 36 
hrs of TNF-α treatment and it steadily increased until 72hrs of treatment. This data is in 
agreement with the higher expression of Midkine during inflammatory response which is 
responsible for increased permeability (Fig. 4.5) (Salaru et al., 2013; Salaru et al., 2016). 
In conclusion, our data shows ECs monolayer disruption is due to increased expression of 
MIDKINE. This data is in agreement with previous studies which reported the increased 




Figure 4.5. Summary of inflammatory response in ECs, Inflammatory stimuli (TNF-α) induces activation and 
translocation of NF-κB into nucleus. NF-κB along with BRD4 protein transcribe pro-inflammatory markers including 1: I-
CAM, VCAM-I, which express on ECs monolayer and bind to monocytes from blood 2: MIDKINE, which contributes in 
recruitment of monocytes and activates p38MAPK mediated disruption of tight junctions in ECs and increase the 
permeability of ECs monolayer.  
 
As our data showed that BRD4 inhibition is protecting ECs monolayer from inflammation 
and protecting monolayer integrity. We were interested to analyse what is the effect of 
BRD4 inhibition on expression of Midkine. Our data shows that pre-treatment with RVX208 
or JQ1 significantly reduces the expression of Midkine at mRNA and protein levels. On the 
basis of these results we concluded that BRD4 inhibition not only protecting ECs from 
inflammatory phenotype but also protecting their barrier function via reducing the 
expression of Midkine (Fig. 4.6). Taken together, further animal studies should be 
conducted to analyses effect of BRD4 in-vivo to decide whether BRD4 inhibition could be 










Figure 4.6 BRD4 inhibition reduces the expression of pro-inflammatory markers: Small molecular inhibitors of 
BRD4 binds to BRD4 bromodomains and inhibits its binding to chromatin, which reduces the expression of pro-
inflammatory markers and protects ECs from activation and tight junction disruption.  
 
Next, we wanted to study the role of PTP1B, a target of BRD4 and NF-κB pathway and it 
has been reported to be overexpressed during inflammation (Zabolotny et al., 2008). 
PTP1B is a phosphatase which is ubiquitously expressed in mammalian tissues and is 
responsible for activation and deactivation of multiple signalling pathways (Zabolotny et 
al., 2008). PTP1B dephosphorylates insulin receptor, EGFR/VEGFR receptor, platelet 
derived growth factor receptor (PDGFR), Colony stimulating factor 1 receptor (CSFR-1), 
and insulin growth factor receptor (IGFR) (Fig. 4.7). In ECs, PTP1B overexpression leads 
to ECs dysfunction, inhibition of VEGFR2 signalling pathway resulting in impaired ECs 
migration and angiogenesis (Lanahan et al., 2014; Thiebaut et al., 2016; Zabolotny et al., 
2008). PTP1B inhibition protects the mice from developing atherosclerotic plaques 






Figure 4.7 PTP1B target receptors: PTP1B dephosphorylates insulin receptor, VEGFR receptor, PDGFR, CSF1R, 
IGF-1R receptor and regulates metabolic pathways, cytoskeleton organization, cell proliferation and survival. (Figure 
published by Tiganis et al., 2007).  
 
We observed significantly higher expression of PTP1B gene and protein in HUVECs, when 
treated with TNF-α. These results are in agreement with previous studies on muscle 
myoblasts cell line (C2C12) and adipose tissues, which showed over expression of PTP1B 
when treated with TNF-α (Panzhinskiy et al., 2013; Zabolotny et al., 2008).  
PTP1B inhibition studies have shown it as a promising approach in treatment of obesity, 
diabetes, hypertension, ECs dysfunction, cardiac dysfunction, and cardiac inflammation 
(Ali et al., 2009; Bruder-Nascimento et al., 2015; Coquerel et al., 2014). A recent study by 
Gogiraju et al., 2016 showed ECs specific deletion of PTP1B (Endo.Ptp1b.KO) protects 
the mice from cardiac hypertrophy and cardiac fibrosis in TAC model (Gogiraju et al., 
2016). However, it was intriguing to further investigate the proteins and pathways which 
were affected in Endo.Ptp1b.KO heart tissues. To answer this, we performed a quantitative 
global proteome analysis on wild type and Endo.Ptp1b.KO mice with and without induced 





Our proteomic analysis could identify 899 proteins in all four groups (WT-SHAM, WT-TAC, 
KO-SHAM, KO-TAC) with differential expression, however with 1% FDR we could quantify 
and consider only 697 proteins for further analysis. Previously, proteomic studies on TAC 
mice reported 538 proteins (Dai et al., 2013). As per our knowledge this is the first study 
to show cardiac proteome analysis of ECs with Ptp1b specific deletion.  
Our data showed only 8 up-regulated and 58 down-regulated proteins in KO-SHAM as 
compared to WT-SHAM. Pathway analysis showed that all these proteins do not belong to 
one specific pathway but included interesting targets like Gap junction alpha-1 protein, 
Calnexin, ribosomal proteins, Glutathione oxidase and cytoskeleton proteins. Gap junction 
alpha-1 protein (GJA1), also known as connexin43, is one of the major cardiac gap junction 
protein and a marker of cardiac lineage (Eshkiki et al., 2017; Kurtenbach et al., 2014). It 
has been reported that PTP1B knock down results in overexpression of GJA1 which 
interrupts the embryonic stem cells differentiation towards cardiac lineage (Eshkiki et al., 
2017). Interestingly, a previous study has reported that reduced expression of GJA1 is a 
marker of congestive heart failure (Kurtenbach et al., 2014). In line with these previous 
observations, our data showed 2-fold up-regulation of GJA1 in KO-SHAM as compared to 
WT-SHAM which may indicate improved cardiac gap junctions in Ptp1b KO animals. 
Calnexin is an endoplasmic reticulum (ER) membranous protein which is responsible for 
folding of secretory and membrane bounded proteins (Lee et al., 2015). It has been 
reported that Calnexin forms a complex with C-terminal of PTP1B and act as an anchor of 
PTP1B in ER (Lee et al., 2015). We observed a 2-fold decreased expression of Calnexin 
in KO-SHAM. This data suggests that KO of PTP1B leads to down-regulation of Calnexin 
through unknown mechanism. Moreover, it has also been reported that Calnexin-PTP1B 
interaction recruits PTP1B to ribosome-translocon complex ensuring its post-translation 
modification role on various targets (Lee et al., 2015). Ribosome translocon complex 
includes ribosomal subunits like 60S and 40S (Voorhees et al., 2014). Interestingly we 
observed reduced expression of multiple ribosomal protein of 60S subunit (Proteins: P1, 
L4, L27A and L29) and of 40S subunit (S4, S9 and S16) up to 1.5-fold to 2-fold. However, 
we did not find any translocon protein to be down-regulated. Oxidative stress leads to 
inactivation of PTP1B via its oxidation (Geraghty et al., 2013). Glutathione peroxidase 
(Gpx) is a common intracellular antioxidant enzyme which has higher activity in response 
to inflammatory stimuli and oxidative stress (Geraghty et al., 2013; Mobasher et al., 2013). 




during induced hepatotoxicity and cells show increased antioxidant defence (Mobasher et 
al., 2013). We observed 2-fold down-regulation of Gpx in KO-SHAM tissues which may 
indicate that Ptp1b deletion protects the hearts against ROS stress. PTP1B is known to 
regulate adhesion and migration of cells via dephosphorylation of cytoskeleton proteins 
like Actin, Filamin C, Cofilin and Fibrinogen (Arregui et al., 2013; Sumi et al., 1999; Wang 
et al., 2018). Cellular movements depend on polymerisation and depolymerisation of actin 
cytoskeleton (Sumi et al., 1999). VEGFR phosphorylation leads to activation of p38MAPK 
pathway which induces actin polymerisation via phosphorylates of cofilin, an acting binding 
protein (Wang et al., 2018). PTP1B is a regulator of VEGFR signalling and PTP1B deletion 
from ECs leads to increased phosphorylation of VEGFR (Gogiraju et al., 2016; Lanahan 
et al., 2014). Interestingly we found that in absence of PTP1B multiple cytoskeleton 
proteins are more than 2-fold down-regulated including fibrinogen and actin related 
proteins: cofilin and filamin C. This data shows that absence of PTP1B may not only affect 
the cytoskeleton proteins function but also might affect their expression. Hence, further 
studies are important to answer these observations. 
Next, we analysed WT-SHAM and WT-TAC proteins and our data showed 60 up-regulated 
and 70 down-regulated proteins in WT-TAC as compared to WT-SHAM. Multiple previous 
studies analysed TAC hearts for global proteome, however, we reported highest number 
of differentially regulated proteins in WT-TAC mice which is 130 proteins as compared to 
previously reported 123 (proteomics study) and 95 (transcriptomics + proteomics study) 
(Dai et al., 2013; Lau et al., 2018). Pathway analysis showed that up-regulated proteins 
exhibit one cluster of cytoskeleton proteins. It has been reported previously that pressure 
overloaded hearts exhibit increased density of microtubules component which contributes 
to stiffness of cardiac muscle (Dai et al., 2013; Lau et al., 2018; Tagawa et al., 1997). We 
observed some interesting cytoskeleton proteins in WT-TAC, including Myosin heavy 
chain, Four and a half LIM domains 1 (FHL1) and β-Tubulin, to be up-regulated. 
Myosin is a main molecule of thick filament of cardiac muscle which generates movement 
by hydrolysis of ATP (Gupta, 2007). Myosin consists of 2 heavy chains (MHCs) (encoded 
by gene α and β) and four light chains (MLCs) (Gupta, 2007; Mahdavi et al., 1984). In 
rodents β-MHC expresses predominantly in ventricles and before birth, expression of α-
MHC starts to increase in ventricles and dominates in young rodents (Gupta, 2007). 
Isoform shift of Myosin from α-MHC to β-MHC is an important hallmark of hypertrophy 




in β-MHC in WT-TAC as compared to WT-SHAM further validating our proteome analysis. 
Four and a half LIM domain proteins domain (FHL) proteins, such as FHL1 are non-
enzymatic proteins associated with cytoskeleton (McGrath et al., 2006). Higher expression 
of FHL1 at transcriptome and proteome level is considered as a marker of cardiac 
hypertrophy (Dai et al., 2013; Lau et al., 2018). We observed 4-fold up-regulation of FHL1 
in WT-TAC mice as compared to WT-SHAM. On the other hand Tubulin protein is a dimer 
of α- and β-tubulin and it has been reported that β-tubulin expression is high in human 
failing hearts with cardiac hypertrophy (Aquila-Pastir et al., 2002). We also observed 2.4-
fold higher expression of β-tubulin in hypertrophic TAC mice.  
Interestingly in down-regulated proteins of WT-TAC, we observed one major cluster 
consisting of mitochondrial associated proteins. Previous studies have also reported that 
pressure overloaded hearts have mitochondrial dysfunction due to down-regulation of 
oxidation-reduction associated proteins, fatty acid metabolism proteins and electron 
transport chain associated proteins (Dai et al., 2013; Lau et al., 2018). Mitochondrial 
dynamics change during cardiac remodelling in CVDs (Vasquez-Trincado et al., 2016). 
Myocardial infarction, atherosclerosis, diabetic cardiomyopathy and cardiac hypertrophy 
poses increased energy demand stress on mitochondria in cardiac tissue which leads to 
cell death, mitochondrial DNA damage, and metabolic disorder, respectively (Fig. 4.8) 







Figure 4.8 Mitochondrial dysfunction in CVDs: CVDs leads to extensive cardiac remodelling and metabolic stress on 
cardiac tissues. In myocardial infarction cardiac cells are deprived of oxygen and nutrients which leads to mitochondrial 
permeability transition pore opening ((mPTP) causing cell death. Cardiac tissues face higher ROS in atherosclerosis 
which cause mitochondrial DNA damage. In diabetic cardiomyopathy, apoptosis is high due to increased ROS 
production. In cardiac hypertrophy, pressure overload leads to increase demand of mitochondrial biogenesis and energy 
production and failure of it leads to increase demand of mitochondrial biogenesis and energy production and failure leads 
to metabolic dysfunction in hypertrophic hearts (Figure published by Vasquez et al., 2016). 
 
Previously, proteomic study and IPA analysis on pressure overload heart showed 
attenuated mitochondrial function, oxidative phosphorylation and Rho based actin 
cytoskeleton polymerisation (RhoGDI signalling) and Rho GTPase signalling (Dai et al., 
2013). In support of these findings our WT-TAC data after IPA analysis showed similar 
results (Fig.4.9). We observed attenuated pathways including oxidative phosphorylation (p 
value 5.19 e-05), mitochondrial dysfunction (p value 1.97 e-04), RhoGDI signalling (p value 
2.19 e-04), and Rho Family GTPases signalling (p value 6.15 e-04) (Fig. 4.9). 
Furthermore, IPA analysis revealed a list of possible phenotypic symptoms on the basis of 
differentially regulated proteins which includes cardiac arrythmia, dilation, heart failure, 





resemble to TAC induced cardiac hypertrophy in WT mice hearts. This data also validates 











Figure 4.9 IPA analysis of WT-TAC proteins compared to WT-SHAM proteins: IPA analysis showing top canonical 
pathways attenuated in WT-TAC (upper panel) which includes oxidative phosphorylation, mitochondrial dysfunction, 
RhoGDI signalling and RhoGTPases signalling. IPA analysis also revealed cardiotoxic effect of these proteins and 
pathways in WT-TAC resembling to hypertrophic heart properties (lower panel). 
 
Further on we analysed which proteins could be more significantly differentially regulated 
in our proteome data causing above mentioned mitochondrial dysfunction. In support of 
this hypothesis, we observed in our down-regulated protein data some mitochondrial 
associated proteins which have been previously reported to be down-regulated during 
pressure overload. NADH dehydrogenase is a largest enzyme complex consisting of 
almost 44 subunits and functions in mitochondrial Electron Transport Chain (ETC). It has 
been reported that NADH dehydrogenase 1- β subcomplex subunit 4 is down-regulated in 
pressure overloaded failing hearts (Bugger et al., 2010). Interestingly, we found also this 
protein to be 2.3-fold downregulated in our WT-TAC samples. Moreover, we found also 
another subunit, NADH dehydrogenase 1- β subcomplex subunit 1, to be down-regulated 
up to 2-fold.  
ATP synthase subunit delta is a subunit of mitochondrial ATP synthase enzyme which is 





et al., 2010). We observed 2.2-fold down-regulation of ATP synthase subunit delta in WT-
TAC. It has been reported that pressure overloaded hearts exhibit down-regulation of 
multiple fatty acid β oxidation pathway proteins at transcriptome and proteome level (Lau 
et al., 2018). We observed multiple fatty acid metabolism associated enzymes to be down-
regulated in WT-TAC mice including 3-ketoacyl-CoA thiolase (2.79-fold), Methylcrotonoyl-
CoA carboxylase (2.62-fold), Carboxylesterase 1 (2.5-fold), Enoyl-CoA delta isomerase 1 
(2.3-fold) and biosynthesis O-methyltransferase (2.02-fold). These findings show that WT-
TAC had impaired fatty acid metabolism, yet another hallmark of hypertrophy (Lau et al., 
2018). Collectively, our data showed down-regulation of above-mentioned proteins which 
have been reported previously in WT-TAC mice. However, we observed many other 
mitochondrial associated proteins which have not been reported previously such as ATP 
binding cassette protein (3.34-fold), Phospholemman (2.12-fold), Sodium/calcium 
exchanger 1 (2.09), Glutaryl-CoA dehydrogenase (1.86-fold), Acyl-coenzyme A 
thioesterase 2 (1.86-fold), Enoyl-CoA hydratase (1.77-fold), Hydroxyacyl-coenzyme A 
dehydrogenase (1.76-fold), Acetyl-coenzyme A synthetase (1.55-fold) etc. Together with 
the known mitochondrial proteins, all these down-regulated proteins confirm that WT-TAC 
mice have mitochondrial dysfunction and impaired metabolic pathways. 
Table 4.1 shows the comparison of some published studies with our proteomic study, we 
observed similar pattern of proteins in WT-TAC as published already in different proteomic 
studies.  
Table 4.1. Comparison of our proteomic results with different published LC-MS/MS based 
proteomic studies on TAC animals  
 
  Dao-Fu Dai  
  et al., 2013 
  Dao-Fu Dai  
  et al., 2012 
 Rüdebusch 
  et al., 2017 
 Bugger et al., 
2009 
 Our study 
Animal model   C57BL6 mice C57BL6 mice   C57BL6 mice   Sprague-Dawley 
   Rat 




  28   28   56   140   140 
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Next, we analysed 2 groups having PTP1B deficiency, namely SHAM and TAC. 
Previously, Gogiraju et al., 2016 reported reduced fibrosis and hypertrophy in KO-TAC. 
We observed different proteome in KO-TAC as compared to KO-TAC and we found 150 
up-regulated and 53 downregulated proteins. Pathway analysis showed that up-regulated 
proteins includes mitochondrial proteins, proteasome associated proteins and proteins 
involved in secretion and transportation. In down-regulated proteins we observed small 
clusters of mitochondria, cytoskeleton, and ribosomal proteins.  
As mentioned above WT-TAC mice having higher expression of β-MHC (up to 22-fold) is 
a major hallmark of cardiac hypertrophy. Unexpectedly, we also observed increased 
expression of β-MHC (up to 7-fold) in KO-TAC, however, this up regulation is 3-fold less 
as compared to WT-TAC. Even though PTP1B deficiency in mice is protecting from cardiac 
fibrosis and hypertrophy, still TAC surgery might be inserting pressure overload on cardiac 




compared to SHAM mice. TAC surgery exhibits pressure on cardiac tissues which leads 
to increased mitochondrial biogenesis to compensate the energy demand (Rosca et al., 
2013). However hypertrophic hearts exhibit reduced mitochondrial biogenesis which leads 
to cellular death (Rosca and Hoppel, 2013). Our data suggest that KO hearts have 
increased mitochondrial biogenesis and have balance between energy demand and 
production. KO-TAC mice hearts also showed over-expression of proteasome associated 
proteins. Proteasomal over-expression can be related to over-expression of proteins in 
TAC mice to degrade misfolded proteins. However, it has also been reported that down-
regulation of PTP1B improves the proteasomal function in neuroblastoma cell lines (Jeon 
et al., 2017). So, over-expression of proteasomal subunits could be an effect of PTP1B 
deficiency, in general. 
PTP1B-deficient mice hearts are protected from hypertrophy and fibrosis as compared to 
WT-TAC. Proteome analysis between WT-TAC and KO-TAC mice showed 43 up-
regulated and 36 down-regulated proteins in KO-TAC as compared to WT-TAC. STRING 
analysis showed mitochondrial cluster in up-regulated proteins while in down-regulated 
proteins showed cluster of ribosomal and cytoskeleton proteins. This data is quite 
interesting and related to previous discussion that KO-TAC showed less hypertrophy and 
fibrosis as compared to WT-TAC. Mitochondrial dysfunction is associated with pressure 
overload in human and mice hearts (Dai et al., 2013; Dai et al., 2012; Lau et al., 2018). 
Our data showed PTP1B deficiency leads to improved mitochondrial function via increased 
expression of mitochondrial proteins.  
Previously 10 subunits of NADH were found downregulated in WT-TAC mice (Dai et al., 
2012). We observed 9 subunits of NADH dehydrogenase to be up-regulated in KO-TAC. 
We observed some other mitochondrial up-regulated proteins like 3 subunits of 
Cytochrome b-c1 complex, 3-ketoacyl-CoA thiolase, Cytochrome c oxidase, ATP-synthase 
subunit delta, Hydroxyacyl-coenzyme A dehydrogenase and NADH-ubiquinone 
oxidoreductase.  
Some other interesting up-regulated proteins include 26S proteasome complex, which 
have been reported to protect mice from cardiac hypertrophy (Dickhout and Austin, 2006). 
We also observed up-regulation of Sepiapterin reductase, a crucial enzyme in (6R)‐l‐
erythro‐5,6,7,8‐tetrahydrobiopterin (BH4) biosynthesis (Sumi-Ichinose et al., 2017). BH4 




hypertrophy, and fibrosis in a 5-week-old pressure induced hypertrophy model (Moens et 
al., 2008; Sumi-Ichinose et al., 2017). Overexpression of Sepiapterin reductase in KO-TAC 
indicates that PTP1B deficiency in ECs may improving the eNO production which is 
contributing in reducing the oxidative stress, fibrosis, and hypertrophy. FHL1 a marker of 
cardiac hypertrophy and was up to 1.77-fold downregulated in KO-TAC as compared to 
WT-TAC. Glucose transporter 4 (GLUT4) is responsible for glucose uptake and deficiency 
of it leads to cardiac hypertrophy (Wende et al., 2017). We observed up-regulation of 
GLUT4 in KO-TAC mice as compared to WT-TAC showing improved glucose metabolism 
in KO-TAC. 
Among down-regulated proteins, we identified multiple ribosomal proteins. As discussed 
previously that PTP1B deficiency leads to reduced expression of ribosomal proteins. 
However, as PTP1B deficient hearts have reduced fibrosis and hypertrophy, this might be 
the reason that there is reduced protein biosynthesis machinery. KO-TAC mice also 
showed down-regulation of cytoskeleton associated proteins, notably β-MHC, a hallmark 
of hypertrophy, was down-regulated in KO-TAC as compared to WT-TAC. Elevated levels 
of Integrin linked kinase, that physically links β-integrins with the actin cytoskeleton, have 
been reported in human cardiac hypertrophy and induces hypertrophy in mice (Lu et al., 
2006). In line with these observations, we found up to 3-fold down-regulation of integrin 
linked kinase in KO-TAC as compared to WT-TAC. It has been reported that there is an 
increase in transcription of β1- and β2-tubulin genes in cardiac hypertrophy (Narishige et 
al., 1999). We observed 2.98-fold down-regulation of Tubulin-β in KO-TAC as compared 
to WT-TAC. Other than cytoskeleton associated proteins we also observed that KO-TAC 
mice have decreased expression Carbonic Anhydrase I and II (CA-I and CA-II) as 
compared to WT-TAC. Carbonic Anhydrases (CAs) are a group of enzymes which .are 
responsible for the reversible conversion of CO2 and H2O in HCO3- and H+. Inhibition of 
CAs in rats showed reduced hypertrophy. CA-II expression is high in cardiac hypertrophic 
mice (Alvarez et al., 2013). Interestingly, human hypertrophic ventricles show increased 
expression of CA-II and CA-IV expression (Alvarez et al., 2013). In our study we found that 
KO-TAC mice have decreased expression CA-I and CA-II as compared to WT-TAC 






Figure 4.10 Summary of global proteome comparison in WT-TAC and KO-SHAM: TAC operation induces 
hypertrophy in wild type hearts (upper panel) due to up-regulation of cytoskeleton associated proteins and mitochondrial 
dysfunction due to down-regulation of mitochondrial proteins related to electron transport chain (ETC), ATP synthesis 
and Fatty acid metabolism. However, Ptp1b.KO mice hearts (lower panel) do not develop hypertrophy and fibrosis in 
response to TAC due to up-regulation of mitochondrial proteins and down-regulation of cytoskeleton associated proteins.  
 
In summary our proteome data strongly supports that PTP1B deficiency protects the mice 
from cardiac hypertrophy and fibrosis due to improved mitochondrial function and reduced 
cytoskeleton density (Fig. 4.10). To support these observations, we performed in vitro 
studies using PTP1b inhibitor in ECs to confirm the improved mitochondrial function. We 
observed that TNF-α treatment induces the mitochondrial functional stress which leads to 
reduced production of ATP. This observation is supported a study by Kalogeris et al., 2014, 
who reported decrease in ATP production and mitochondrial mass in ECs in response to 
TNF-α (Kalogeris et al., 2014). Furthermore, we were able to analyse successfully that 
PTP1B inhibition prior to TNF-α treatment in ECs protects the cells from mitochondrial 
dysfunction as well as the restoration of ATP production. 
In conclusion our study elaborates that BRD4 inhibition reduces the inflammation and 
could be a therapeutic target for atherosclerosis. Furthermore, PTP1B inhibition improves 
the cardiac function in pressure overloaded hearts by improving the mitochondrial function 






Figure 4.11 Conclusion: TNF-α, BRD4 and PTP1B function on ECs and CVDs: Upper Panel :TNF-α induces 
activation of NF-κB, BRD4 and NF-κB transcribe inflammatory markers, Midkine and PTP1B. Increased expression of 
inflammatory markers and Midkine contributes in ECs dysfunction and monolayer disruption. Increased expression of 
PTP1B is known for reduced expression of eNOS and VEGFR signalling, an indication of ECs dysfunction. Increased 
activity of PTP1B have been reported to be associated with reduced cardiac contractile function, reduced ATP 
production, increased cardiac fibrosis, hypertrophy, ECs dysfunction, hypoxia and heart failure. Lower Panel: Our data 
showed RVX208/JQ1 based BRD4 inhibition reduces the expression of inflammatory markers, Midkine and it protects 
ECs monolayer from disruption. Further studies should be conducted to analyse the effect of BRD4 inhibition on PTP1B 
expression. Our data showed that PTP1B inhibition with Claramine recovers the ATP production loss induced by TNF-α 
treatment. Our data showed the Endo.Ptp1b.KO reduces the cardiac hypertrophy and fibrosis by reducing the 
cytoskeleton associated protein expression and increasing the mitochondrial protein expression to compensate the 









Vascular and lymphatic system is lined by Endothelial cells (ECs) monolayer or 
endothelium. Healthy endothelium maintains vessel functions by releasing different 
substances including Nitric Oxide (NO). Cardiovascular risk factors induce ECs 
dysfunction, which leads to the increase permeability of ECs and development of 
atherosclerosis. In response to inflammatory stimulus, NF-κB signalling pathway becomes 
activated. NF-κB signalling is responsible for releasing cytokines and expressing adhesion 
molecules on ECs surface.  BRD4 is a chromatin regulator transcription factor, which binds 
to super enhancers of basal cell state maintaining gene loci. BRD4 redistributes on 
chromatin during inflammation and along with NF-κB binds to super enhancers of 
inflammatory gene loci.   
In the present study, we analysed the role of BRD4 and its isoforms in ECs dysfunction 
and investigated whether BRD4 inhibition restores ECs function under inflammation-
stimulating conditions. We established an in vitro model of inflammatory phenotype using 
he treatment of HUVECs with TNF-α. Our study indicates that BRD4 short isoform is 
overexpressed in HUVECs during inflammation along with increased expression of 
inflammatory markers, Midkine, and PTP1B. Pre-treatment with BRD4 inhibitors (JQ1 and 
RVX-208) abrogates ECs activation and dysfunction via reducing the expression of pro 
inflammatory markers. We also observed that TNF-α treated HUVECs showed increased 
permeability which indicates disrupted monolayer integrity. In contrast, monolayer integrity 
was retained when HUVECs pre-treated with BRD4 inhibitors.  
Elevated levels of Midkine has been reported in human and mice atherosclerotic plaques. 
It has also been reported to disrupt monolayer integrity via activation of downstream 
signalling pathways. HUVECs secrete Midkine when treated to 48-72 hours with TNF-α. 
BRD4 inhibition with JQ1 and RVX208 reduced the Midkine secretion indicating BRD4 
inhibition is retaining the monolayer integrity by reduce Midkine signalling. As far as we 
know, this is the first study that identified the role of BRD4 in regulation of Midkine, an 
upstream regulator of p38MAPK signalling pathway. Our data pointed out that an orally 
administered RVX208 drug can contribute in atherosclerosis treatment. Our study gives 






Our results confirms the previous observations stating PTP1B inhibition is beneficial in 
ECs, in-vitro and in-vivo. This is the first study to report the heart global proteome of 
PTP1B-deficient mice and its contribution in prevention of cardiac fibrosis and hypertrophy. 
Our data shed light on cardio-protective role of PTP1B deletion by identifying the 
improvement of mitochondrial function in cardiac hypertrophy animals. Furthermore, this 
report proved in in-vitro study that PTP1B inhibition improves the ATP production in ECs. 
From our results, it can be suggested that PTP1B inhibition can be a therapeutic option in 
prevention of cardiac fibrosis and hypertrophy after myocardial infarction. This study 
provides essential understanding into beneficial roles of BRD4 and Ptp1b in CVDs, 
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7. Supplementary material 
 
Fig. S1. Full view of STRING analysis of Group A, WT-SHAM vs KO-SHAM proteome. Analysis of protein 
interaction network by STRING, Coloured lines between the proteins indicate the protein co-occurrence, co-
expression, known interactions and predicted interactions. Up-regulated proteins do not present any specific 
interaction or cluster (A) however Interconnecting ribosomal proteins (red circle) represents a functionally associated 






Fig. S2. Full view of STRING analysis of Group B, WT-SHAM vs WT-TAC proteome (up-regulated). Analysis of protein 
interaction network by STRING, Coloured lines between the proteins indicate the protein co-occurrence, co-expression, 
known interactions and predicted interactions. Up-regulated proteins show interconnecting mitochondrial proteins (blue 
circle) represents a functionally associated protein cluster, while cytoskeleton associated proteins are showing another 











Fig. S3. Full view of STRING analysis of Group B, WT-SHAM vs WT-TAC proteome (down-regulated). Analysis of 
protein interaction network by STRING, Coloured lines between the proteins indicate the protein co-occurrence, co-
expression, known interactions and predicted interactions. Interconnecting mitochondrial proteins (blue circle) represents a 










Fig. S4. Full view of STRING analysis of Group C, KO-SHAM vs KO-TAC proteome (up-regulated). Analysis of protein 
interaction network by STRING, Coloured lines between the proteins indicate the protein co-occurrence, co-expression, 
known interactions and predicted interactions. Up-regulated proteins show interconnecting major cluster (red circle) 
represents multiple enzymes involved in metabolic pathways and cytoskeleton associated proteins while, mitochondrial 
proteins (blue circle) represents a functionally associated protein cluster, while proteasome associated proteins are showing 





Fig. S5. Full view of STRING analysis of Group C, KO-SHAM vs KO-TAC proteome (down-regulated). Analysis of 
protein interaction network by STRING, Coloured lines between the proteins indicate the protein co-occurrence, co-
expression, known interactions and predicted interactions. Interconnecting major clusters show mitochondrial proteins (blue 





Fig. S6. Full view of STRING analysis of Group D, WT-TAC vs KO-TAC proteome (up-regulated). Analysis of 
protein interaction network by STRING, Coloured lines between the proteins indicate the protein co-occurrence, co-
expression, known interactions and predicted interactions. Up-regulated proteins show Interconnecting major cluster 
shows mitochondrial proteins (blue circle) . Interconnecting major clusters show ribosomal proteins (yellow circle) and 










Fig. S7. Full view of STRING analysis of Group D, WT-TAC vs KO-TAC proteome (down-regulated). Analysis of 
protein interaction network by STRING, Coloured lines between the proteins indicate the protein co-occurrence, co-
expression, known interactions and predicted interactions. Interconnecting major clusters show ribosomal proteins 
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